

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	6	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	11	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	12	JUL 28	EPFULL enhanced with additional legal status information from the EPOLINE Register
NEWS	13	JUL 28	IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS	14	JUL 28	STN Viewer performance improved
NEWS	15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	16	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	18	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	21	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	23	SEP 29	IFICLS enhanced with new super search field
NEWS	24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents

NEWS 26 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 27 OCT 07 Multiple databases enhanced for more flexible patent
number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:45:58 ON 09 OCT 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:46:10 ON 09 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 OCT 2008 HIGHEST RN 1058345-57-5

DICTIONARY FILE UPDATES: 7 OCT 2008 HIGHEST RN 1058345-57-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10553982 broadest.str



chain nodes :

21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 23

chain bonds :

2-21 4-17 5-11 21-22 21-23

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15

15-16 16-17

exact/norm bonds :

1-2 1-5 2-3 2-21 3-4 4-5 4-17 5-11 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17 21-22 21-23

isolated ring systems :

containing 1 : 6 : 12 :

G1:C,N

G2:O,S

G3:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 21:CLASS 22:CLASS
23:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.46	0.67

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:46:28 ON 09 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Oct 2008 VOL 149 ISS 15
FILE LAST UPDATED: 8 Oct 2008 (20081008/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s L1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 07:46:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 39686 TO ITERATE

100.0% PROCESSED 39686 ITERATIONS 936 ANSWERS
SEARCH TIME: 00.00.01



L2 936 SEA SSS FUL L1

L3 35 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 35 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:859080 CAPLUS Full-text
DOCUMENT NUMBER: 149:176324
TITLE: Preparation of substituted diarylpyrazole derivatives
for use as cannabinoid-CB1 antagonists and serotonin
reuptake inhibitors
INVENTOR(S): Lange, Josephus H. M.; Kruse, Cornelis G.
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: PCT Int. Appl., 51pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008084057	A1	20080717	WO 2008-EP50181	20080109
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
US 20080214559	A1	20080904	US 2008-970229	20080107
PRIORITY APPLN. INFO.:			EP 2007-100323	A 20070110
			US 2007-879533P	P 20070110
OTHER SOURCE(S):			MARPAT 149:176324	
GI				



AB Title compds. I [X = (un)substituted (un)saturated carbon chain containing 0 to 8 atoms, where one carbon atom may be replaced with N, O, or S; R¹ = H or alkyl; or together with the N atom to which it is attached, and together with part of X, form heterocycloalkyl or heteroaryl; R² = an essential structural element of any known cannabinoid-CB₁ antagonist; R³ = an essential structural element of any known serotonin reuptake inhibitor; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as cannabinoid-CB₁ antagonists and serotonin reuptake inhibitors. Thus, e.g., II was prepared by amination of 4-chloro-1-(5-fluoro-1H-indol-3-yl)butan-1-one (preparation given) with piperazine, followed by reduction and amidation with 2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazole-4-carboxylic acid (preparation given). I were evaluated in human cannabinoid-CB₁ receptor binding assays, e.g., II demonstrated a pK_i values of 7.5. I were disclosed as therapeutic agents for psychosis, anxiety, depression, attention deficits, cognitive disorders, obesity, drug dependence, Parkinson's disease, Alzheimer's disease, pain disorders, neuropathic pain disorders and sexual disorders.


IT 1039037-40-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted diarylpyrazole derivs. for use as cannabinoid-CB₁ antagonists and serotonin reuptake inhibitors useful in the treatment of diseases)

RN 1039037-40-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-[4-(5-fluoro-1H-indol-3-yl)butyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:614722 CAPLUS Full-text
DOCUMENT NUMBER: 148:561719
TITLE: Preparation of pyrrole derivatives, particularly
4,5-diphenylpyrrole-2-carboxamides, as CB1 cannabinoid
receptor antagonists
INVENTOR(S): Barth, Francis; Congy, Christian; Hortala, Laurent;
Rinaldi, Carmona Murielle
PATENT ASSIGNEE(S): Sanofi Aventis, Fr.
SOURCE: Fr. Demande, 39pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
FR 2908766	A1	20080523	FR 2006-10202	20061120
WO 2008068423	A2	20080612	WO 2007-FR1888	20071119
WO 2008068423	A3	20080731		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: FR 2006-10202 A 20061120
OTHER SOURCE(S): MARPAT 148:561719
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = (un)substituted alkylene, phenylene, benzylene, etc.; R1 = H, alkyl; R2 = (un)substituted alkyl, indanyl, monooxygen, monosulfur, mononitrogen 5-7 membered heterocyclyl, benzhydryl, benzhydrylmethyl, etc.; or NR1R2 = morpholinyl, (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl, piperidin-1-yl, pyrrolidin-1-yl; R3-R8 = independently H, halo, alkoxy, (un)substituted alkyl SO0-2-alkyl, OSO0-2-alkyl; R9 = OH, CN, CO2H, NH2 and derivs., CONH2, SO2CF3, NHSO2CF3, CONHOH, etc.; their free bases and their acid addition salts, and their hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors (no data) and for treatment of the diseases it implies (no data). Thus, a multi-step synthesis starting from 2-amino-3-butynoic acid was given for pyrrole II (m.p. = 102°). I exhibited an excellent affinity in vitro (IC50 ≤ 5•10⁻⁷ M) for the CB1 cannabinoid receptors. The antagonist nature of compds. I was demonstrated by adenylate-

cyclase inhibition models, and toxicity was compatible with therapeutic use (no data). The interaction of I with the brain CB1 receptors was determined using a test of ex vivo binding of [3H]-CP55940 after i.v. injection to mice (no data). The interaction of I with the peripheral CB1 receptors was determined using a test of reversion of the inhibiting effect of CP55940 on gastrointestinal transit after oral administration to mice (no data). Thus, I are useful for treating psychiatric, metabolic, and gastrointestinal disorders, smoking cessation, etc. (no data).


IT 1026666-10-3P, 1'-[[5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]-1,4'-bipiperidiny-4'-carboxamide
1026666-11-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of diphenylpyrrole carboxamides as antagonists of CB1 cannabinoid receptors)


RN 1026666-10-3 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



RN 1026666-11-4 CAPLUS

CN 1H-Pyrrole-1-hexanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)-, ethyl ester (CA INDEX NAME)



IT 1026665-87-1P 1026665-88-2P 1026665-90-6P
1026665-91-7P 1026665-92-8P 1026665-93-9P
1026665-95-1P 1026665-96-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of diphenylpyrrole carboxamides as antagonists of CB1 cannabinoid receptors)



RN 1026665-87-1 CAPLUS

CN 1H-Pyrrole-1-hexanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 1026665-88-2 CAPLUS

CN 1H-Pyrrole-1-propanoic acid, 5-[[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]carbonyl]-2-(4-chlorophenyl)-3-(2,4-dichlorophenyl)- (CA INDEX NAME)




RN 1026665-90-6 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-1-(2-cyanoethyl)-4-(2,4-dichlorophenyl)-1H-pyrrol-2-yl]carbonyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1026665-89-3


CMF C31 H32 C13 N5 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1026665-91-7 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)




RN 1026665-92-8 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-bromophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)




RN 1026665-93-9 CAPLUS

CN Methanone, [4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl][5-(4-bromophenyl)-4-(2,4-dichlorophenyl)-1-[2-(methylsulfonyl)ethyl]-1H-pyrrol-2-yl]- (CA INDEX NAME)





RN 1026665-95-1 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[3-[(methylsulfonyl)amino]propyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



RN 1026665-96-2 CAPLUS

CN [1,4'-Bipiperidine]-4'-carboxamide, 1'-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-[3-[(trifluoromethyl)sulfonyl]amino]propyl]-1H-pyrrol-2-yl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1209410 CAPLUS Full-text
 DOCUMENT NUMBER: 147:486462
 TITLE: Preparation of imidazolylcarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators
 INVENTOR(S): Berger, Richard; Edmondson, Scott; Hansen, Alexa; Zhu, Cheng
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 112pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120655	A2	20071025	WO 2007-US8832	20070410
WO 2007120655	A3	20080925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,

KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK,
 MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
 RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:



US 2006-791961P

P 20060414

OTHER SOURCE(S):

MARPAT 147:486462

GI



AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R4 = independently H, halo, alkyl, etc.; R5-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently halo, CN, alkyl, etc.; m = 1-4; n = 0-4; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

IT 1057345-59-1 1057345-61-5


RL: PRPH (Prophetic)

(Preparation of imidazolylcarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators)

RN 1057345-59-1 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1057345-61-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-, methyl ester (CA INDEX NAME)



IT 954397-95-6P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid
 954397-96-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate
 954398-00-6P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid
 954398-01-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate
 954398-05-1P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid
 954398-06-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate
 954398-11-9P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid
 954398-12-0P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid trifluoroacetate
 954398-16-4P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid
 954398-17-5P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid trifluoroacetate
 954398-22-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid
 954398-23-3P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid trifluoroacetate
 954398-28-8P 954398-34-6P 954398-47-1P,

3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-1-naphthoic acid 954398-48-2P,
 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidin-4-yl]-1-naphthoic acid trifluoroacetate
 954398-68-6P, 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-1-naphthoic acid 954398-69-7P, 3-[1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxypiperidin-4-yl]-1-naphthoic acid trifluoroacetate 954398-77-7P,
 1-(7-Methoxy-2-naphthyl)-4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperazine 954398-79-9P,
 3-[4-[[1-(3-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954398-81-3P, Methyl
 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate 954398-83-5P, 6-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954398-85-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-isopropyl-1-naphthalenecarboxamide 954398-87-9P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(1-pyrrolidinyl)carbonyl]-2-naphthyl]piperazine 954398-89-1P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-1-naphthalenecarboxamide 954398-91-5P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-1-naphthalenecarboxamide 954398-93-7P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[3-[(1-pyrrolidinyl)carbonyl]-2-naphthyl]piperazine 954398-94-8P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-2-naphthalenecarboxamide 954398-96-0P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-2-naphthalenecarboxamide 954398-98-2P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-isopropyl-2-naphthalenecarboxamide 954399-00-9P, 3-[4-[[2-(2,4-Difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954399-02-1P, 3-[4-[[1-(3-Hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-04-3P, 3-[4-[[1-(3-Ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-06-5P, 3-[4-[[2-(4-Chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoic acid 954399-08-7P, 3-[4-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoic acid 954399-22-5P 954399-24-7P 954399-26-9P
 954399-28-1P 954399-30-5P 954399-32-7P
 954399-34-9P 954399-36-1P 954399-38-3P
 954399-40-7P 954399-42-9P 954399-44-1P
 954399-46-3P 954399-48-5P 954399-51-0P
 954399-53-2P 954399-55-4P 954399-57-6P
 954399-60-1P 954399-63-4P 954399-66-7P
 954399-69-0P 954399-72-5P 954399-75-8P
 954399-78-1P 954399-81-6P 954399-84-9P
 954399-87-2P 954399-90-7P 954399-93-0P
 954399-96-3P 954399-99-6P 954400-02-3P
 954400-05-6P 954400-08-9P 954400-11-4P
 954400-14-7P 954400-17-0P 954400-20-5P
 954400-23-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1

receptor modulators)

RN 954397-95-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954397-96-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954397-95-6


CMF C34 H32 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-00-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-01-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-00-6


CMF C34 H31 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-05-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-06-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 954398-05-1


CMF C33 H29 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-11-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-12-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-11-9


CMF C33 H28 F2 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-16-4 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-17-5 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 954398-16-4


CMF C33 H29 F N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-22-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-23-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 954398-22-2


CMF C34 H32 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-28-8 CAPLUS

CN β -D-Glucopyranuronic acid, 1-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenecarboxylate] (CA INDEX NAME)

Absolute stereochemistry.



RN 954398-34-6 CAPLUS


CN D-Aspartic acid, N-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-33-5

CMF C38 H37 N5 O7


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-47-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954398-48-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-47-1


CMF C35 H32 F N3 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954398-68-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]- (CA INDEX NAME)




RN 954398-69-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-hydroxy-4-piperidinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-68-6


CMF C35 H32 F N3 O5



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 954398-77-7 CAPLUS

CN Methanone, [4-(7-methoxy-2-naphthalenyl)-1-piperazinyl][1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 954398-79-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-81-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)




RN 954398-83-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954398-85-7 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 954398-87-9 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 954398-89-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl- (CA INDEX NAME)




RN 954398-91-5 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl- (CA INDEX NAME)




RN 954398-93-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthalenyl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 954398-94-8 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl- (CA INDEX NAME)




RN 954398-96-0 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl- (CA INDEX NAME)




RN 954398-98-2 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 954399-00-9 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-02-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-04-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-06-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 954399-08-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 954399-22-5 CAPLUS

CN Methanone, [4-(7-methoxy-2-naphthalenyl)-1-piperazinyl][1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-77-7


CMF C33 H32 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-24-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-79-9


CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-26-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 2-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-81-3


CMF C34 H32 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-28-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 6-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-83-5


CMF C34 H32 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-30-5 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-85-7


CMF C37 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-32-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-1-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-87-9


CMF C38 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-34-9 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-89-1


CMF C36 H37 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-36-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-91-5


CMF C38 H41 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-38-3 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N,N-diethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-94-8


CMF C38 H41 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-40-7 CAPLUS

CN Methanone, [3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthalenyl]-1-pyrrolidinyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-93-7


CMF C38 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-42-9 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-ethyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-96-0


CMF C36 H37 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-44-1 CAPLUS

CN 2-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954398-98-2


CMF C37 H39 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-46-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-00-9


CMF C33 H28 F2 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-48-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-02-1


CMF C32 H28 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-51-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-50-9


CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-53-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-04-3


CMF C33 H30 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-55-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 954399-06-5


CMF C33 H29 Cl N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-57-6 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-08-7


CMF C34 H31 F N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-60-1 CAPLUS

CN 1-Naphthalenecarbonitrile, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-59-8


CMF C34 H31 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-63-4 CAPLUS

CN Methanesulfonamide, N-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-62-3


CMF C34 H35 N5 O4 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954399-66-7 CAPLUS
 CN 2-Propanesulfonamide, N-[3-[4-[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954399-65-6
 CMF C36 H39 N5 O4 S



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954399-69-0 CAPLUS
 CN Methanone, [4-(4-amino-2-naphthalenyl)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954399-68-9
 CMF C33 H33 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-72-5 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-[4-(2H-tetrazol-5-yl)-2-naphthalenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-71-4


CMF C34 H32 N8 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-75-8 CAPLUS


CN α -D-Glucopyranuronic acid, 1-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenecarboxylate], 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-74-7

CMF C40 H40 N4 O10


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-78-1 CAPLUS

CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N- β -D-galactopyranosyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954399-77-0
 CMF C40 H43 N5 O8

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954399-81-6 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-[4-(hydroxymethyl)phenyl]-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954399-80-5
 CMF C34 H32 N4 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-84-9 CAPLUS


CN 2-Propenoic acid, 3-[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]-, (2E)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-83-8

CMF C36 H34 N4 O4


Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-87-2 CAPLUS


CN 1-Naphthalenepropanoic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-

1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 954399-86-1


CMF C36 H36 N4 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-90-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,3-dihydroxypropyl)-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-89-4


CMF C37 H39 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-93-0 CAPLUS


CN D-Glucitol, 1-deoxy-1-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-92-9

CMF C40 H45 N5 O8


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954399-96-3 CAPLUS

CN β-D-Glucopyranose, 2-deoxy-2-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-


methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-95-2

CMF C40 H43 N5 O8


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954399-99-6 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954399-98-5


CMF C40 H41 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-02-3 CAPLUS

CN Propanedioic acid, 2-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-01-2


CMF C37 H35 N5 O7



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-05-6 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(2S)-2,3-dihydroxypropyl]-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-04-5

CMF C37 H39 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-08-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954400-07-8
CMF C40 H43 N5 O6

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 954400-11-4 CAPLUS
CN 1-Naphthalenecarboxamide, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954400-10-3
CMF C37 H39 N5 O5



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-14-7 CAPLUS


CN 1-Naphthalenecarboxamide, N-[(1S,2R,3S,4S)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]-3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-13-6

CMF C40 H43 N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 954400-17-0 CAPLUS


CN L-Aspartic acid, N-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-16-9

CMF C38 H37 N5 O7


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-20-5 CAPLUS

CN Propanoic acid, 3-[[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]amino]-2-hydroxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-19-2


CMF C37 H37 N5 O6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954400-23-8 CAPLUS

CN 1-Naphthaleneacetic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954400-22-7


CMF C35 H34 N4 O4




CM 2

CRN 76-05-1


CMF C2 H F3 O2



IT 954397-98-9P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate
 954398-03-9P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate
 954398-09-5P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate trifluoroacetate
 954398-14-2P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(2,4-difluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthoate
 954398-20-0P, Methyl 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoate trifluoroacetate
 954398-26-6P, Methyl 3-[4-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-2-naphthoate trifluoroacetate
 954398-31-3P 954398-65-3P, Methyl 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidin-4-yl]-1-naphthoate trifluoroacetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1 receptor modulators)
 RN 954397-98-9 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)




RN 954398-03-9 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)



RN 954398-09-5 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954398-08-4
 CMF C34 H31 F N4 O4




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 954398-14-2 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[4-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)



RN 954398-20-0 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954398-19-7
 CMF C34 H31 F N4 O4



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954398-26-6 CAPLUS
 CN 2-Naphthalenecarboxylic acid, 3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954398-25-5
 CMF C35 H34 N4 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954398-31-3 CAPLUS

CN D-Aspartic acid, N-[[3-[4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-1-naphthalenyl]carbonyl]-, 1,4-bis(phenylmethyl) ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954398-65-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954398-64-2

CMF C36 H34 F N3 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2





L3 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1207584 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 147:486461
 TITLE: Preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators
 INVENTOR(S): Berger, Richard; Edmondson, Scott; Hansen, Alexa; Zhu, Cheng
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 125pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120688	A2	20071025	WO 2007-US8901	20070410
WO 2007120688	A3	20080717		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 PRIORITY APPLN. INFO.: US 2006-791962P P 20060414
 OTHER SOURCE(S): MARPAT 147:486461
 GI



AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R4 = independently H, halo, alkyl, etc.; R5-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently (hetero)aryl; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

IT 954409-74-6P, (2S)-1-[[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(quinolin-3-yl)-2-piperazinecarboxylic acid trifluoroacetate 954409-88-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators)

RN 954409-74-6 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-73-5

CMF C33 H31 N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-88-2 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-(3-quinolinyl)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 954409-73-5P 954409-80-4P, N-Ethyl-(2S)-1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(quinolin-3-yl)piperazine-2-carboxamide trifluoroacetate 954409-82-6P
 954409-83-7P 954409-85-9P 954409-86-0P
 954409-93-9P 954409-94-0P 954409-98-4P
 954409-99-5P 954410-05-0P 954410-15-2P
 954410-16-3P 954410-17-4P 954410-18-5P
 954410-33-4P, 4-(4-Carboxy-2-naphthyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinecarboxylic acid trifluoroacetate 954410-55-0P 954410-57-2P
 954410-59-4P 954410-61-8P 954410-64-1P

954410-66-3P 954410-68-5P 954410-70-9P
 954410-72-1P 954410-74-3P 954410-76-5P
 954410-78-7P 954410-80-1P 954410-82-3P
 954410-84-5P 954410-85-6P 954410-86-7P
 954410-87-8P 954410-88-9P 954410-90-3P
 954410-91-4P 954410-93-6P 954410-95-8P
 954410-97-0P 954410-99-2P 954411-00-8P
 954411-03-1P 954411-04-2P 954411-06-4P
 954411-08-6P 954411-11-1P 954411-13-3P
 954411-15-5P 954411-17-7P 954411-20-2P
 954411-22-4P 954411-25-7P 954411-28-0P
 954411-30-4P 954411-33-7P 954411-36-0P
 954411-38-2P 954411-41-7P 954411-44-0P
 954411-46-2P 954411-48-4P 954411-49-5P
 954411-51-9P 954411-53-1P 954411-55-3P
 954411-58-6P 954411-60-0P 954411-63-3P
 954411-66-6P 954411-69-9P 954411-71-3P
 954411-73-5P 954411-74-6P 954411-75-7P
 954411-83-7P 954411-84-8P 954411-85-9P
 954411-86-0P 954411-87-1P 954411-88-2P
 954411-89-3P 954411-90-6P 954411-91-7P
 954411-92-8P 954411-93-9P 954411-94-0P
 954411-95-1P 954411-96-2P 954411-97-3P
 954411-99-5P 954412-00-1P 954412-01-2P
 954412-03-4P 954412-04-5P 954412-05-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as
 cholecystinin-1 receptor modulators)

RN 954409-73-5 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-
 imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-80-4 CAPLUS


CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-
 imidazol-4-yl]carbonyl]-N-ethyl-4-(3-quinolinyl)-, (2S)-,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-79-1

CMF C35 H36 N6 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-82-6 CAPLUS

CN Glycine, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-83-7 CAPLUS
 CN Glycine, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]carbonyl]-,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954409-82-6
 CMF C35 H34 N6 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 954409-85-9 CAPLUS
 CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-86-0 CAPLUS


CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-85-9

CMF C35 H35 N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-93-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-94-0 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(methylethyl)amino]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)

CM 1


CRN 954409-93-9
 CMF C38 H39 N5 O5

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 954409-98-4 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-99-5 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-98-4


CMF C38 H39 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 954410-05-0 CAPLUS
CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954410-04-9
CMF C37 H36 N4 O7


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954410-15-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954410-16-3 CAPLUS


CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954410-15-2

CMF C37 H36 F N5 O5


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954410-17-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 954410-18-5 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(1-methylethyl)amino]carbonyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1)
 (CA INDEX NAME)

CM 1


CRN 954410-17-4
 CMF C38 H38 F N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 954410-33-4 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954410-32-3


CMF C36 H33 N3 O6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954410-55-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-57-2 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-59-4 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-61-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-64-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-66-3 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-68-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-methyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-70-9 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-methyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-72-1 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-ethyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-74-3 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-diethyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-76-5 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-diethyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-78-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-(1-methylethyl)-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-80-1 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-(1-methylethyl)-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-82-3 CAPLUS

CN 2-Piperazinecarboxamide, N-(1,1-dimethylethyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-84-5 CAPLUS

CN 2-Piperazinecarboxamide, N-(1,1-dimethylethyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-85-6 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-propyl-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-86-7 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-propyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-87-8 CAPLUS

CN 2-Piperazinecarboxamide, N-butyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-88-9 CAPLUS

CN 2-Piperazinecarboxamide, N-butyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-90-3 CAPLUS

CN Methanone, [(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]-1-piperidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-91-4 CAPLUS


CN Methanone, [1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]-1-pyrrolidinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-93-6 CAPLUS
 CN Methanone, [(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-95-8 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N,N-dimethyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954410-97-0 CAPLUS
 CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-pentyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-99-2 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-N-hexyl-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-00-8 CAPLUS

CN 2-Piperazinecarboxamide, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-N-2H-tetrazol-5-yl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-03-1 CAPLUS

CN 2-Piperazinecarboxamide, N-cyclopropyl-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-04-2 CAPLUS

CN 2-Piperazineacetic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-06-4 CAPLUS


CN 2-Piperazineacetic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-08-6 CAPLUS
CN Methanone, [(2R)-2-[(acetyloxy)methyl]-4-(3-quinolinyl)-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-11-1 CAPLUS
CN Acetic acid, 2-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-13-3 CAPLUS
CN Acetamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 954411-15-5 CAPLUS
CN Acetamide, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-17-7 CAPLUS

CN Propanamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-2-methyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 954411-20-2 CAPLUS

CN Cyclopropanecarboxamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 954411-22-4 CAPLUS

CN Cyclopentanecarboxamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-25-7 CAPLUS

CN Benzamide, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-28-0 CAPLUS

CN Urea, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-N'-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-30-4 CAPLUS

CN Urea, N-[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-N'-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-33-7 CAPLUS

CN Urea, N-[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]-N'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-36-0 CAPLUS

CN Methanesulfonamide, N-[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-38-2 CAPLUS

CN Methanesulfonamide, N-[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-41-7 CAPLUS

CN Cyclopropanesulfonamide, N-[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-44-0 CAPLUS

CN Glycine, N-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-46-2 CAPLUS

CN Glycine, N-[[[(2R)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-2-piperazinyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-48-4 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-[[2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinolinyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954411-49-5 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-(3-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 954411-51-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-53-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-55-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[(1-methylethyl)amino]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 954411-58-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-60-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[2-[(1-methylethyl)amino]-2-oxoethyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-63-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[2-[(1-methylethyl)amino]-2-oxoethoxy]methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 954411-66-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[(methylsulfonyl)amino]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-69-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[(methylamino)carbonyl]amino]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-71-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-73-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-74-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[[(methylsulfonyl)amino]methyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954411-75-7 CAPLUS


CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[[(methylamino)carbonyl]amino]methyl]-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 954411-83-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthalenyl)- (CA INDEX NAME)




RN 954411-84-8 CAPLUS

CN Acetic acid, 2-[[[1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-4-piperidinyl]oxy]- (CA INDEX NAME)




RN 954411-85-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)]-4-piperidinyl]oxy]acetic acid (CA INDEX NAME)




RN 954411-86-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(methyldiamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-87-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(dimethylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-88-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(1-methylethylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-89-3 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[(methylamino)carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954411-90-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[(dimethylamino)carbonyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954411-91-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(cyclopropylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-92-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(ethylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-93-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(phenylamino)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-94-0 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[(diethylamino)carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-95-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[[[(carboxymethyl)amino]carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-96-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[[[(carboxymethyl)methylamino]carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954411-97-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-(1-pyrrolidinylcarbonyl)-2-naphthalenyl]- (CA INDEX NAME)




RN 954411-99-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-(4-morpholinylcarbonyl)-2-naphthalenyl]- (CA INDEX NAME)




RN 954412-00-1 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-(4-carboxy-2-naphthalenyl)-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954412-01-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-[[[(carboxymethyl)amino]carbonyl]-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 954412-03-4 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-[[[(carboxymethyl)amino]carbonyl]-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)




RN 954412-04-5 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[4-(aminocarbonyl)-2-naphthalenyl]-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 954412-05-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[4-(aminocarbonyl)-1-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)



IT 954409-89-3 954410-07-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystinin-1 receptor modulators)

RN 954409-89-3 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-07-2 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 954409-59-7P 954409-60-0P 954409-61-1P, Benzyl

(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)piperazine-1-carboxylate 954409-62-2P, Benzyl

(3R)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperazine-1-carboxylate 954409-77-3P,

Methyl (2S)-1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(quinolin-3-yl)piperazine-2-carboxylate trifluoroacetate

954409-91-7P 954409-92-8P 954409-97-3P

954410-00-5P 954410-01-6P 954410-02-7P

954410-03-8P 954410-06-1P 954410-08-3P
954410-09-4P 954410-10-7P 954410-11-8P
954410-12-9P 954410-13-0P 954410-14-1P
954410-20-9P 954410-45-8P, Methyl 4-[4-

[(benzyloxy)carbonyl]-2-naphthyl]-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]piperidine-4-carboxylate


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperazinylcarbonyl and piperidinylcarbonyl imidazoles as cholecystokinin-1 receptor modulators)

RN 954409-59-7 CAPLUS

CN Methanone, [(2R)-2-[(acetyloxy)methyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-60-0 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[(phenylmethoxy)carbonyl]-, methyl ester, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-61-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-, phenylmethyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-62-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 954409-77-9 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-, (2S)-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954409-76-8

CMF C34 H33 N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954409-91-7 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl] [(2S)-2-(hydroxymethyl)-4-(3-quinoliny)-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954409-92-8 CAPLUS

CN Acetic acid, 2-[[[(2S)-1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(3-quinoliny)-2-piperazinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954409-97-3 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(methylethyl)amino]carbonyl]-1-piperazinyl]-, methyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954409-96-2
 CMF C39 H41 N5 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954410-00-5 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 954410-01-6 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[[2-(1,1-dimethylethoxy)-2-oxoethoxymethyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A

RN 954410-02-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(carboxymethoxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, 1-methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 954410-03-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-4-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[2-(methylamino)-2-oxoethoxy]methyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 954410-06-1 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-[4-[[[tris(1-methylethyl)silyl]oxy]methyl]-2-naphthalenyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-08-3 CAPLUS

CN Methanone, [(2S)-2-[(acetyloxy)methyl]-4-[4-(hydroxymethyl)-2-naphthalenyl]-1-piperazinyl][1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-09-4 CAPLUS

CN 1-Naphthalenecarboxaldehyde, 3-[(3S)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-10-7 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-[(acetyloxy)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-11-8 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-(hydroxymethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-12-9 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3S)-3-(azidomethyl)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-13-0 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-(aminomethyl)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 954410-14-1 CAPLUS

CN 1-Naphthalenecarboxylic acid, 3-[(3R)-3-[(acetylamino)methyl]-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 954410-20-9 CAPLUS
 CN 1-Naphthalenecarboxylic acid, 3-[(3S)-4-[[1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-3-[[1-(methylethyl)amino]carbonyl]-1-piperazinyl]-, methyl ester,
 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954410-19-6
 CMF C39 H40 F N5 O5

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1
 CMF C2 H F3 O2





RN 954410-45-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-[4-[(phenylmethoxy)carbonyl]-2-naphthalenyl]-, methyl ester (CA INDEX NAME)



L3 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1207445 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 147:486460
TITLE: Preparation of imidazolylcarbonyl naphthylpiperazine derivatives as cholecystokinin-1 receptor modulators
INVENTOR(S): Duffy, Joseph L.; Edmondson, Scott; Hansen, Alexa; Zhu, Cheng
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 78pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007120718	A2	20071025	WO 2007-US8956	20070410
WO 2007120718	A3	20080724		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2006-792134P P 20060414
OTHER SOURCE(S): CASREACT 147:486460; MARPAT 147:486460
GI



AB Title compds. represented by the formula I [wherein X = N or CR16; R1-R7 = independently H, halo, OH, alkyl(oxy); R8 = H, halo, alkoxy or (cyclo)alkyl; R9, R16 = independently H, alkyl, Ph, etc.; R10 = independently halo, CN, alkyl, etc.; m = 0-4; n = 0-4; and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin-1 receptor (CCK-1R) modulators. For example, II was provided in a multi-step synthesis starting from the reaction of 3-ethoxyaniline with p-tolunitrile. I were tested and found to bind to the CCK-1R with IC50 values less than or equal to 500 nM; and have EC50 values less than or equal to 500 nM in the functional assay. Thus, I and their pharmaceutical compns. are useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.

IT 954382-77-5P, 1-[[2-(2,4-Difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-79-7P, 1-[[1-(3-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-80-0P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-81-1P, 1-[[1-(3-Hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-82-2P, 1-[[1-(2,3-Dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-83-3P, 1-[[1-(3-Isopropoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-84-4P, 1-[[1-(3-Ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-85-5P, 1-[[1-(4-Methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-86-6P, 1-[[1-(3-Ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-87-7P, 1-[[1-(3-Ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-88-8P, 1-[[1-(3-Ethoxyphenyl)-2-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-89-9P, 1-[[1-(3-Ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-90-2P, 1-[[1-(3-Ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-91-3P, 1-[[1-(3-Ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-92-4P, 1-[[1-(3-Ethoxyphenyl)-2-(4-trifluoromethylphenyl)-1H-imidazol-4-


yl]carbonyl]-4-(2-naphthyl)piperazine 954382-93-5P,
 1-[[1-(3-Ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-4-(2-naphthyl)piperazine 954382-98-0P
 954383-00-7P 954383-01-8P 954383-02-9P
 954383-03-0P 954383-04-1P 954383-05-2P
 954383-06-3P 954383-07-4P 954383-08-5P
 954383-09-6P 954383-10-9P 954383-11-0P
 954383-12-1P 954383-13-2P 954383-14-3P
 954383-15-4P 954383-16-5P 954383-21-2P
 954383-22-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolylcarbonyl naphthylpiperazines as cholecystokinin-1 receptor modulators)


RN 954382-77-5 CAPLUS

CN Methanone, [2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-79-7 CAPLUS

CN Methanone, [1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-80-0 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-81-1 CAPLUS

CN Methanone, [1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-82-2 CAPLUS

CN Methanone, [1-(2,3-dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-83-3 CAPLUS

CN Methanone, [1-[3-(1-methylethoxy)phenyl]-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-84-4 CAPLUS

CN Methanone, [1-(3-ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-85-5 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-86-6 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-87-7 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-88-8 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-89-9 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-90-2 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-91-3 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-92-4 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 954382-93-5 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954382-98-0 CAPLUS

CN Methanone, [2-(2,4-difluorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-77-5


CMF C32 H28 F2 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-00-7 CAPLUS

CN Methanone, [1-(3-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-79-7


CMF C32 H30 N4 O2




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 954383-01-8 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 954382-80-0
 CMF C33 H32 N4 O2



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 954383-02-9 CAPLUS
 CN Methanone, [1-(3-hydroxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 954382-81-1
 CMF C31 H28 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-03-0 CAPLUS

CN Methanone, [1-(2,3-dimethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-82-2


CMF C33 H32 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-04-1 CAPLUS

CN Methanone, [1-[3-(1-methylethoxy)phenyl]-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-83-3


CMF C34 H34 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-05-2 CAPLUS

CN Methanone, [1-(3-ethylphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-84-4


CMF C33 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-06-3 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-85-5


CMF C32 H30 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954383-07-4 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954382-86-6
 CMF C32 H29 F N4 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954383-08-5 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-phenyl-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954382-87-7
 CMF C32 H30 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-09-6 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(3-ethoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-88-8


CMF C32 H29 Cl N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 954383-10-9 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluorophenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 954382-89-9
 CMF C32 H29 F N4 O2



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 954383-11-0 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-(4-ethylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 954382-90-2
 CMF C34 H34 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 954383-12-1 CAPLUS

CN Methanone, [1-(3-ethoxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954382-91-3


CMF C33 H32 N4 O3




CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 954383-13-2 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 954382-92-4
 CMF C33 H29 F3 N4 O2



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 954383-14-3 CAPLUS
 CN Methanone, [1-(3-ethoxyphenyl)-2-(2-fluoro-4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)
 CM 1
 CRN 954382-93-5
 CMF C33 H31 F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954383-15-4 CAPLUS

CN Methanone, [1-(3-ethoxy-5-fluorophenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954383-16-5 CAPLUS

CN Methanone, [1-(3-ethoxy-5-fluorophenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954383-15-4


CMF C33 H31 F N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 954383-21-2 CAPLUS

CN Methanone, [1-(3-fluoro-5-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 954383-22-3 CAPLUS

CN Methanone, [1-(3-fluoro-5-methoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl][4-(2-naphthalenyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 954383-21-2


CMF C32 H29 F N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L3 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:11808 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 146:121964
 TITLE: Imidazole based LXR modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Busch, Breet B.; Flatt, Brenton T.; Gu, Xiao Hui; Lu, Shao Po; Martin, Richard; Mohan, Raju; Nyman, Michael Charles; Schweiger, Edwin; Stevens, William C., Jr.; Wang, Tie Lin; Xie, Yinong
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002563	A1	20070104	WO 2006-US24757	20060626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM

AU 2006261845	A1	20070104	AU 2006-261845	20060626
CA 2613522	A1	20070104	CA 2006-2613522	20060626
EP 1910308	A1	20080416	EP 2006-785562	20060626




R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS

MX 200800141	A	20080407	MX 2008-141	20071219
IN 2007DN10015	A	20080620	IN 2007-DN10015	20071224
KR 2008039381	A	20080507	KR 2008-701879	20080124
CN 101248049	A	20080820	CN 2006-80030791	20080222

PRIORITY APPLN. INFO.: US 2005-694372P P 20050627
US 2005-736120P P 20051110
WO 2006-US24757 W 20060626

OTHER SOURCE(S): MARPAT 146:121964

GI



AB Compds. of the invention, such as compds. of formulas I, II, III and IV and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed. Compds. of formulas I - IV wherein R1 is (un)substituted (hetero)aryl, (un)substituted C3-8 cycloalkyl, (un)substituted alkyl, (un)substituted acyl, (un)substituted thioacyl, sulfonyl, ether, etc.; R2 and R21 are independently (un)substituted alkyl, (un)substituted alkylidyl, H, halo, NO₂, (hetero)aryl, etc.; R3 is (un)substituted alkyl, (un)substituted alkylidyl, (un)substituted (hetero)aryl, CN, etc.; G is (un)substituted (hetero)aryl, (un)substituted (hetero)biaryl, (un)substituted alkylaryl, etc.; and their pharmaceutically acceptable salts, isomers, and prodrugs thereof are claimed. Example compound V was prepared by addition of 2,5-dichloroaniline to 5-bromothiophene-2-carbonitrile; the resulting 5-bromo-N-(2,5-dichlorophenyl)thiophene-2-carboxamide underwent cyclization with 1-bromo-3,3,3-trifluoroacetone to give 2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-4,5-dihydro-1H-imidazol-4-ol, which underwent dehydration to give 2-(5-bromothiophen-2-yl)-1-(2,5-dichlorophenyl)-4-trifluoromethyl-1H-imidazole,, which underwent Suzuki

cross-coupling with 3-methylsulfonylphenylboronic acid to give compound V. All the invention compds. were evaluated for their LXR modulatory activity. From the assay, it was determined that several of the tested compound exhibited IC50 values of < 1 μ M. Compds. of the invention, such as compds. of Formulas Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compns. containing the compds. and methods of using the compds. are also disclosed.


IT 918348-97-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole based LXR modulators and their use in the treatment of diseases)

RN 918348-97-7 CAPLUS

CN Methanone, [2-(2,6-dichlorophenyl)-1-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:677655 CAPLUS Full-text

DOCUMENT NUMBER: 145:124571

TITLE: preparation of imidazoles and pyrazoles as CB1 and/or CB2 cannabinoid receptor ligands.

INVENTOR(S): Makriyannis, Alexandros; Thotapally, Rajesh; Vemuri, Venkata Kiran Rao; Olszewska, Teresa

PATENT ASSIGNEE(S): Vemuri, Venkata, Kiran, Rao, USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006074445	A2	20060713	WO 2006-US720	20060110
WO 2006074445	A3	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 AU 2006203845 A1 20060713 AU 2006-203845 20060110
 CA 2594488 A1 20060713 CA 2006-2594488 20060110
 EP 1845972 A2 20071024 EP 2006-733658 20060110
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2008526887 T 20080724 JP 2007-550544 20060110
 IN 2007CN03498 A 20071116 IN 2007-CN3498 20070810
 PRIORITY APPLN. INFO.: US 2005-642544P P 20050110
 WO 2006-US720 W 20060110
 OTHER SOURCE(S): MARPAT 145:124571
 GI



AB Title compds. e.g. [I; A, B = bond, O, (CH₂)₁R₅; B = bond, O, NR₅; R₅ = H, (substituted) alkyl; l = 0, 1; R₁, R₂ = (CH₂)_nZ; n = 0-7; Z = H, halo, N₃, NCS, cyano, NO₂, OAc, acyloxy, aroyloxy, acylamino, alkoxy, substituted carbocyclyl, heterocyclyl, etc.; R₃ = specified 5-6 membered ring, bicycloheptyl, adamantyl, fused ring system, etc.; R₄ = H, halo, N₃, NCS, Ph, cyano, NO₂, carbocyclyl, heterocyclyl, aryl, heteroaryl, azabicycloheptyl, etc.], were claimed. Thus, title compound (II) showed CB₁ receptor binding with K_i = 1.2 nM.
 IT 897924-76-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of imidazoles and pyrazoles as CB₁ and/or CB₂ cannabinoid receptor ligands)
 RN 897924-76-4 CAPLUS
 CN Methanone, [1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:543547 CAPLUS Full-text
 DOCUMENT NUMBER: 145:1063
 TITLE: Imidazole derivatives for the treatment of dementia
 and related disorders
 INVENTOR(S): Fathi, Zahra
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060203	A2	20060608	WO 2005-US42008	20051118
WO 2006060203	A3	20061214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2004-632025P P 20041130

OTHER SOURCE(S): MARPAT 145:1063

AB The invention discloses imidazole derivs. which are useful in treating dementia and related disorders.


IT 527372-06-1 527372-06-1D, esters and salts
 527373-26-8 527373-26-8D, esters and salts
 527378-40-1 527378-40-1D, esters and salts
 527378-56-9 527378-56-9D, esters and salts
 527378-73-0 527378-73-0D, esters and salts
 527378-78-5 527378-78-5D, esters and salts
 527379-22-2 527379-22-2D, esters and salts
 527379-58-4 527379-58-4D, esters and salts
 527380-53-6 527380-53-6D, esters and salts
 527380-58-1 527380-58-1D, esters and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazole derivs. for treatment of dementia and related disorders, and use with other agents)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)

yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



L3 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:543183 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:1062

TITLE: Imidazole derivatives for treating diseases involving cannabinoid receptor dysregulation

INVENTOR(S): Fathi, Zahra

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2006060190	A2	20060608	WO 2005-US41895	20051118
WO 2006060190	A3	20070802		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2004-632012P P 20041130

OTHER SOURCE(S): MARPAT 145:1062


AB This invention relates to imidazole derivs. which are useful in treating diseases linked to the modulation of the cannabinoid receptors.

IT 527372-06-1 527373-26-8 527378-40-1
527378-56-9 527378-73-0 527378-78-5
527379-22-2 527379-58-4 527380-53-6
527380-58-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(imidazole derivs. for treating diseases involving cannabinoid receptor dysregulation)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



L3 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:542774 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:21208

TITLE: Imidazole derivatives for the treatment of psychiatric disorders

INVENTOR(S): Ortiz, Astrid

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060202	A2	20060608	WO 2005-US42007	20051118
WO 2006060202	A3	20061214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2004-632028P

P 20041130

OTHER SOURCE(S):

MARPAT 145:21208

AB The invention discloses imidazole derivs. which are useful in treating psychiatric disorders.


IT 527372-06-1 527372-06-1D, esters and salts
527373-26-8 527373-26-8D, esters and salts
527378-40-1 527378-40-1D, esters and salts
527378-56-9 527378-56-9D, esters and salts
527378-73-0 527378-73-0D, esters and salts
527378-78-5 527378-78-5D, esters and salts
527379-22-2 527379-22-2D, esters and salts
527379-58-4 527379-58-4D, esters and salts
527380-53-6 527380-53-6D, esters and salts
527380-58-1 527380-58-1D, esters and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(imidazole derivs. for treatment of psychiatric disorders, and use with other agents)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-06-1 CAPLUS


CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-26-8 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-

yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyloxy]- (CA INDEX NAME)



L3 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:542767 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 145:14783

TITLE: Imidazole derivatives for the treatment of sexual dysfunction

INVENTOR(S): Glombitza, Bernhard

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060199	A2	20060608	WO 2005-US42001	20051118
WO 2006060199	A3	20070419		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2004-632001P P 20041130

OTHER SOURCE(S): MARPAT 145:14783


AB This invention relates to imidazole derivs. which are useful in treating sexual dysfunction.

IT 527372-06-1 527373-26-8 527378-40-1
527378-56-9 527378-73-0 527378-78-5
527379-22-2 527379-58-4 527380-53-6
527380-58-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imidazole derivs. for the treatment of sexual dysfunction)


RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)



RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



L3 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:380879 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 144:432814

TITLE: Preparation of 1,5-diheterocyclyl-1H-triazole derivatives as platelet aggregation inhibitors


INVENTOR(S): Kanaya, Naoaki; Fujii, Kunihiro

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006043594	A1	20060427	WO 2005-JP19207	20051019
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005296582	A1	20060427	AU 2005-296582	20051019
CA 2583153	A1	20060427	CA 2005-2583153	20051019
EP 1803719	A1	20070704	EP 2005-795875	20051019
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101039934	A	20070919	CN 2005-80035228	20051019
NO 2007001826	A	20070614	NO 2007-1826	20070410
KR 2007063530	A	20070619	KR 2007-708162	20070410
MX 200704643	A	20070608	MX 2007-4643	20070418
US 20080125409	A1	20080529	US 2007-577476	20070418
PRIORITY APPLN. INFO.:			JP 2004-303851	A 20041019
			WO 2005-JP19207	W 20051019
OTHER SOURCE(S):			MARPAT 144:432814	
GI				




AB The title compds. represented by the general formula (I) [wherein Ar1, Ar2 = (un)substituted 5- or 6-membered aromatic heterocyclyl; R1, R2 = H, each (un)substituted lower alkyl, alicyclic heterocyclyl, carbamoyl, or NH2 HO; or NR1R2 together represents an (un)substituted 4- to 7-membered alicyclic heterocyclyl optionally containing one N or O atom other than the ring N atom], salts thereof, or solvates of either are prepared These compds. are potent platelet aggregation inhibitors which inhibit neither COX-1 nor COX-2, and are useful for the prevention and treatment of ischemic diseases. Thus, 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4- triazole-3-carboxylic acid was condensed with neopentylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, Et3N, and 1-hydroxybenzotriazole in DMF at room temperature for 48 h to give 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazole-3- carboxylic acid N-

neopentylamide (II). II showed IC₅₀ of 0.013 μ M for inhibiting the collagen-induced aggregation of human blood platelet.


IT 787563-08-0P, 1-[[5-(5-Cyano-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-95-6P
 , 1-[[5-(5-Fluoro-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)
 RN 787563-08-0 CAPLUS
 CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884596-95-6 CAPLUS
 CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)




IT 884597-10-8P, 1-[[5-(5-Aminomethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)
 RN 884597-10-8 CAPLUS
 CN Methanone, [5-[5-(aminomethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



IT 884596-93-4P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine
 884596-94-5P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-96-7P
 , 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-97-8P,
 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-98-9P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-3,3-difluoroazetidine
 884596-99-0P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methylpiperazine 884597-06-2P,
 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methyl-3-oxopiperazine 884597-07-3P,
 (2S)-1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-2-fluoromethylpyrrolidine 884597-08-4P,
 4-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]morpholine 884597-09-5P, 1-[[5-(5-Carbamoyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884597-11-9P, 1-[[5-(5-Hydroxymethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)


RN 884596-93-4 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-94-5 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl) [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-96-7 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl) [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-97-8 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl) [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-98-9 CAPLUS

CN Methanone, (3,3-difluoro-1-azetidiny) [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 884596-99-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 884597-06-2 CAPLUS


CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 884597-07-3 CAPLUS


CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 884597-08-4 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)




RN 884597-09-5 CAPLUS

CN 3-Pyridinecarboxamide, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884597-11-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[5-[5-(hydroxymethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:126304 CAPLUS Full-text

DOCUMENT NUMBER: 144:212649

TITLE: Preparation of 4,5-diphenylpyrrole-2-carboxamide derivatives as antagonists of CB1 cannabinoid receptors and their therapeutic application

INVENTOR(S): Barth, Francis; Congy, Christian; Hortala, Laurent; Rinaldi Carmona, Murielle

PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.

SOURCE: Fr. Demande, 26 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2874012	A1	20060210	FR 2004-8773	20040809
FR 2874012	B1	20080822		
AU 2005279086	A1	20060309	AU 2005-279086	20050802
CA 2576717	A1	20060309	CA 2005-2576717	20050802
WO 2006024777	A1	20060309	WO 2005-FR2015	20050802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1781636	A1	20070509	EP 2005-796087	20050802
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101014588	A	20070808	CN 2005-80030251	20050802
JP 2008509202	T	20080327	JP 2007-525320	20050802
BR 2005014235	A	20080603	BR 2005-14235	20050802
US 20070149596	A1	20070628	US 2007-625616	20070122

US 7381727	B2	20080603		
IN 2007KN00337	A	20070706	IN 2007-KN337	20070131
MX 200701383	A	20070419	MX 2007-1383	20070202
NO 2007001209	A	20070305	NO 2007-1209	20070305
KR 2007054649	A	20070529	KR 2007-705467	20070308
US 20080194581	A1	20080814	US 2008-102412	20080414
PRIORITY APPLN. INFO.:			FR 2004-8773	A 20040809
			WO 2005-FR2015	W 20050802
			US 2007-625616	A1 20070122
OTHER SOURCE(S):	MARPAT 144:212649			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl; R2 = alkyl, 1,2,3,4-tetrahydronaphthalen-1-yl, 1,2,3,4-tetrahydronaphthalen-2-yl, (un)substituted heterocyclyl, phenylalkylene, etc.; or NR1R2 = (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl, piperidin-1-yl, pyrrolidin-1-yl; R3-R8 = independently H, halo, alkyl, alkoxy, CF3, etc.; R9 = alkyl; and their free bases, and their acid addition salts, hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors and for treatment of the diseases it implies. For instance, II (m.p. = 165°) was prepared in 7 steps via cyclization of alkyne III (preparation given) in the presence of I2/K2CO3, Pd-coupling with (2,4-dichlorophenyl)boronic acid, Ts-deprotection, alkylation of the pyrrole IV with MeI in the presence of K2CO3/ester hydrolysis (ester not isolated) and amidation of the acid with N-aminopiperidine. I exhibited an excellent affinity in vitro ($IC_{50} \leq 5 \cdot 10^{-7}$ M) for the CB1 cannabinoid receptors. Thus, I are useful for treating psychosis, appetite and gastrointestinal disorders, smoking and alc. cessation, etc.

IT 875667-48-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrrole carboxamide derivs. as antagonists of CB1 cannabinoid receptors)

RN 875667-48-4 CAPLUS

CN Ethanone, 1-[1-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1-methyl-1H-pyrrol-2-yl]carbonyl]-4-phenyl-4-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1154377 CAPLUS Full-text
 DOCUMENT NUMBER: 143:422349
 TITLE: Preparation of imidazole derivatives for promoting smoking cessation
 INVENTOR(S): Gardell, Stephen J.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099705	A2	20051027	WO 2005-US8904	20050318
WO 2005099705	A3	20060119		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-555920P P 20040324
 OTHER SOURCE(S): MARPAT 143:422349
 GI



AB The title compds. I [R1, R2 = (un)substituted Ph, alkyl, (un)substituted cyclohexyl, etc.; R3 = H, alkyl, CH2Ph, Cl, Br; X = CONR4R5 (wherein R4 = H, alkyl; R5 = (un)substituted alkyl, bicycloalkyl, CH2Ph, etc.; or NR4R5 = (un)substituted 5-10 membered (un)saturated heterocyclyl), CONHSO2R10 (R10 = (un)substituted alkyl, Ph, benzocyclohexyl, benzocyclopentyl)] which are useful in promoting smoking cessation and maintaining abstinence, were prepared E.g, a 2-step synthesis of II, starting from 2-chloro-N-(4-chlorophenyl)benzenecarboximidamide and Et 3-bromo-2-oxopentanoate, was given. The pharmaceutical compns. comprising the compound I in combination with one


or more nicotine replacement therapies or one of more nicotinic receptor modulators are disclosed.

IT 527368-74-7P 527368-79-2P 527368-89-4P
527380-29-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazole derivs. for promoting smoking cessation)


RN 527368-74-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]-4-thiomorpholinyl- (CA INDEX NAME)




RN 527368-79-2 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527368-89-4 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 527380-29-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidiny)- (CA INDEX NAME)



IT 527368-13-4P 527368-24-7P 527368-29-2P
527368-32-7P 527368-37-2P 527368-42-9P
527368-46-3P 527368-51-0P 527368-61-2P
527368-84-9P 527368-98-5P 527369-08-0P
527369-13-7P 527371-67-1P 527371-72-8P
527371-76-2P 527371-81-9P 527371-87-5P
527371-91-1P 527371-96-6P 527372-01-6P
527372-06-1P 527372-11-8P 527372-16-3P
527372-21-0P 527372-26-5P 527372-32-3P
527372-35-6P 527372-41-4P 527372-46-9P
527372-49-2P 527372-54-9P 527372-59-4P
527372-63-0P 527372-68-5P 527372-73-2P
527372-77-6P 527372-82-3P 527372-87-8P
527372-92-5P 527372-97-0P 527373-02-0P
527373-06-4P 527373-11-1P 527373-16-6P
527373-20-2P 527373-26-8P 527373-32-6P
527373-36-0P 527373-41-7P 527373-47-3P
527373-52-0P 527373-57-5P 527375-32-2P
527375-37-7P 527375-42-4P 527377-14-6P
527377-19-1P 527377-25-9P 527377-30-6P
527377-34-0P 527377-39-5P 527377-44-2P
527377-49-7P 527377-54-4P 527377-59-9P
527377-63-5P 527377-68-0P 527377-73-7P
527377-78-2P 527377-83-9P 527377-87-3P
527377-92-0P 527377-97-5P 527378-02-5P
527378-07-0P 527378-12-7P 527378-18-3P
527378-22-9P 527378-27-4P 527378-32-1P
527378-36-5P 527378-40-1P 527378-44-5P
527378-48-9P 527378-52-5P 527378-56-9P
527378-60-5P 527378-68-3P 527378-73-0P
527378-78-5P 527378-83-2P 527378-88-7P
527378-93-4P 527378-98-9P 527379-04-0P
527379-08-4P 527379-13-1P 527379-18-6P
527379-22-2P 527379-27-7P 527379-32-4P
527379-37-9P 527379-42-6P 527379-48-2P
527379-52-8P 527379-58-4P 527379-63-1P
527379-67-5P 527379-70-0P 527379-75-5P
527379-80-2P 527379-85-7P 527379-90-4P
527380-00-3P 527380-05-8P 527380-09-2P
527380-14-9P 527380-19-4P 527380-24-1P


527380-34-3P 527380-38-7P 527380-43-4P
527380-48-9P 527380-53-6P 527380-58-1P
868406-23-9P 868406-26-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of imidazole derivs. for promoting smoking cessation)


RN 527368-13-4 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl]-1-
piperidinyl- (CA INDEX NAME)




RN 527368-24-7 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]-1-
piperidinyl- (CA INDEX NAME)




RN 527368-29-2 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-
yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-32-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-37-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-42-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-46-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-51-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(hydroxymethyl)-1-piperidinyloxy]- (CA INDEX NAME)



RN 527368-61-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(diethylamino)-1-pyrrolidinyloxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527368-84-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][1-oxido-4-thiomorpholinyl]- (CA INDEX NAME)




RN 527368-98-5 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527369-08-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527369-13-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-5-ethyl-1-[4-(1-methylethyl)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527371-67-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,3-dimethylphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-72-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-76-2 CAPLUS

CN Benzonitrile, 2-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-81-9 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-87-5 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-91-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-96-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-01-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-11-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 527372-16-3 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(cyclohexyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-21-0 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 527372-20-9
 CMF C27 H20 Cl2 F4 N4 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 527372-26-5 CAPLUS
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-32-3 CAPLUS
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-pyrazinyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 527372-31-2


CMF C25 H22 Cl2 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 527372-35-6 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-41-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(6-methyl-2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)


NAME)



● HCl


RN 527372-46-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-49-2 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-54-9 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-59-4 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-63-0 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinylmethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 527372-68-5 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,5-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-73-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-77-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-


difluorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-82-3 CAPLUS


CN Benzonitrile, 2-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-87-8 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-92-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-97-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 527373-02-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-06-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-11-1 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-16-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-20-2 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-32-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-, hydrochloride (1:1)
(CA INDEX NAME)



● HCl

RN 527373-36-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-41-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-47-3 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-cyclohexyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-52-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl] [4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-57-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-5-methyl-1-(4-nitrophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527375-32-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-37-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl](3-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 527375-42-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 527377-14-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(1,1-dioxidobenzo[b]thien-2-yl)-4-hydroxy-1-piperidiny]- (CA INDEX NAME)




RN 527377-19-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thiazolyl)-1-piperidiny]- (CA INDEX NAME)




RN 527377-25-9 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidiny][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-30-6 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-34-0 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-39-5 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl)[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-44-2 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-49-7 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-54-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-59-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,6-dimethyl-3-pyridinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-63-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-68-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-difluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-73-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-78-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-83-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-87-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-92-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-97-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-02-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-07-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-12-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-18-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-22-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-27-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-32-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-36-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-44-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-52-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-60-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-68-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-fluoro-4-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-83-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-88-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-93-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-98-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-04-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxy-3-methylphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-08-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-13-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-18-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4,6-dimethyl-2-pyrimidinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-27-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-32-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-37-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-42-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-48-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-52-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-63-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-67-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-70-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-75-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-80-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(methylthio)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-85-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-90-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-ethyl-4-hydroxy-1-piperidinyl)- (CA INDEX NAME)




RN 527380-00-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-05-8 CAPLUS

CN Methanone, (4-butyl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-09-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-pentyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-14-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-19-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-24-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-34-3 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-38-7 CAPLUS

CN Methanone, [4-(4-bromophenyl)-4-hydroxy-1-piperidinyl] [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-43-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527380-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 868406-23-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(1-methylpropyl)-1-piperidinyl]- (CA INDEX NAME)




RN 868406-26-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 527384-14-1

CMF C27 H21 Cl2 F3 N4 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L3 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:822141 CAPLUS Full-text
 DOCUMENT NUMBER: 143:229830
 TITLE: Preparation of 1,3-oxazole-2-carboxamide derivatives
 as antagonists of CB1 cannabinoid receptors and their
 therapeutic application
 INVENTOR(S): Barth, Francis; Rinaldi Carmonia, Murielle
 PATENT ASSIGNEE(S): Sanofi-Synthelabo, Fr.
 SOURCE: Fr. Demande, 21 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2866340	A1	20050819	FR 2004-1507	20040213
FR 2866340	B1	20061124		
WO 2005080357	A2	20050901	WO 2005-FR321	20050211
WO 2005080357	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

EP 1716142 A2 20061102 EP 2005-717611 20050211
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 BA, HR, IS, YU

CN 1918153 A 20070221 CN 2005-80004731 20050211
 JP 2007522191 T 20070809 JP 2006-552665 20050211
 US 20070043060 A1 20070222 US 2006-461629 20060801
 US 7320978 B2 20080122
 IN 2006KN02314 A 20070525 IN 2006-KN2314 20060814
 PRIORITY APPLN. INFO.: FR 2004-1507 A 20040213
 WO 2005-FR321 W 20050211


OTHER SOURCE(S): MARPAT 143:229830
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [wherein R1 = H, alkyl; R2 = alkyl, (un)substituted mononitrogen heterocyclyl, phenylalkylene, etc., or NR1R2 = (un)substituted piperazin-1-yl, 1,4-diazepan-1-yl; R3-R8 = independently H, halo, alkyl, CF3, alkoxy, etc.; their free bases or acid addition salts, and their hydrates or solvates] were prepared as antagonists of CB1 cannabinoid receptors and for treatment of the diseases it implies. For instance, II (m.p. = 165°) was prepared in 4 steps by oximation of 2-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)ethanone with NH2OH•HCl, cyclization with monoethyl oxalate chloride in DCM, hydrolysis, and TEA-amidation with 1-aminopiperidine. I exhibited an excellent affinity in vitro (IC50 ≤ 5•10⁻⁷ M) for the CB1 cannabinoid receptors. Thus, I are useful for treating psychosis, appetite and gastrointestinal disorders, smoking and alc. cessation, etc.

IT 862722-84-7P 862722-85-8P 862722-87-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of oxazole carboxamides derivs. as antagonists of CB1 cannabinoid receptors)


RN 862722-84-7 CAPLUS
 CN Methanone, [5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl][4-(3-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 862722-85-8 CAPLUS
CN Methanone, [5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl] (4-hydroxy-4-phenyl-1-piperidiny)- (CA INDEX NAME)



RN 862722-87-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-2-oxazolyl]carbonyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:497497 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 143:43882

TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamide derivatives showing CB1-antagonistic activity and combination treatment involving the compounds

INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Gunter; Lange, Josephus Hubertus Maria; Kruse, Cornelis Gerit

PATENT ASSIGNEE(S): Germany

SOURCE: U.S. Pat. Appl. Publ., 27 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20050124660	A1	20050609	US 2004-969840	20041022
PRIORITY APPLN. INFO.:			US 2003-513995P	P 20031027

OTHER SOURCE(S):
GI

CASREACT 143:43882; MARPAT 143:43882




AB The present invention relates to a novel medical use of compds. with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivs., 1H-imidazole derivs., thiazole derivs. and/or 1H-1,2,4-triazole-3-carboxamide derivs. or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compds. with CB1-receptor activity in combination with lipase inhibitors. Said compds. are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin. I was prepared and other similar compds. were tested for human cannabinoid CB1 receptor affinity and in vitro antagonism.

IT 676457-12-8P 676457-31-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-1,2,4-triazole-3-carboxamide derivs. showing CB1-antagonistic activity)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



L3 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:395074 CAPLUS Full-text
 DOCUMENT NUMBER: 142:447220
 TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as
 cannabinoid-CB1 receptor ligands
 INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald;
 Krause, Guenter; Lange, Josephus Hubertus Maria;
 Kruse, Chris
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 63 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039550	A2	20050506	WO 2004-EP52639	20041022
WO 2005039550	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283056	A1	20050506	AU 2004-283056	20041022
CA 2543338	A1	20050506	CA 2004-2543338	20041022
BR 2004015851	A	20070102	BR 2004-15851	20041022
EP 1753413	A2	20070221	EP 2004-817279	20041022
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
JP 2007513872	T	20070531	JP 2006-536096	20041022
CN 1997364	A	20070711	CN 2004-80030116	20041022
MX 2006PA04434	A	20060620	MX 2006-PA4434	20060421
PRIORITY APPLN. INFO.:			EP 2003-103961	A 20031024
			EP 2003-103967	A 20031027
			WO 2004-EP52639	W 20041022
OTHER SOURCE(S):			MARPAT 142:447220	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The novel use of nitrogen heterocycles I-V [R, R1, R5, R11 = Ph, naphthyl, thienyl, pyridyl, etc.; R2, = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl; R7 = (un)branched alkyl] for treatment of cannabinoid-CB1 receptor related diseases, especially in juveniles, is described. A 4-step synthesis of triazolecarboxamide VI.HCl starting from di-Me aminomalonate.HCl 4-chlorobenzoyl chloride, 2,4-dichloroaniline, and 1-aminopiperidine is given. Furthermore, the invention pertains to the use of I-V in combination with lipase inhibitors. Preferred lipase inhibitors are orlistat, panclicins, ATL-962, and/or lipstatin.


IT 676457-12-8P 676457-31-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazolecarboxamides as cannabinoid-CB1 receptor ligands for treatment of drug-induced obesity in juveniles and adolescents)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)





RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



ACCESSION NUMBER: 2005:220141 CAPLUS Full-text
 DOCUMENT NUMBER: 142:280212
 TITLE: Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders
 INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans, Arnoldus H. J.; Van Stuivenberg, Herman H.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 490,019.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050054679	A1	20050310	US 2004-912171	20040806
US 7109216	B2	20060919		
WO 2003027076	A2	20030403	WO 2002-EP10434	20020917
WO 2003027076	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040235854	A1	20041125	US 2004-490019	20040319
US 20050267161	A1	20051201	US 2005-138289	20050527
PRIORITY APPLN. INFO.:			EP 2001-203851	A 20010921
			WO 2002-EP10434	W 20020917
			US 2004-490019	A2 20040319
			US 2004-574939P	P 20040528
OTHER SOURCE(S):			CASREACT 142:280212; MARPAT 142:280212	
GI				




AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R1 = (un)substituted Ph or pyridinyl; R2 = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R3 = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R3 = pyridinyl or Ph when R4 ≠ H; or R3 = NR5R6 when R2 = H or Me; or NR2R3 = (un)substituted heterocyclyl; R4 = H, halo, CN, carbamoyl, formyl, acetyl, CF3CO, FCH2CO, EtCO, sulfamoyl, MeSO2, MeS, or (un)substituted alkyl; R5 and R6 = independently alkyl; or NR5R6 = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists. For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboximidine (42%). Cyclization of the carboximidine with Et 3-bromo-2-oxopropanoate in a solution of NaHCO3 and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarbonyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH2Cl2 afforded II (26%). Selected I bound to hCB1 receptor with pKi values in the range of 7.0 to 8.4. I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).

IT 505073-33-6P, 1-[[1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]hexahydro-1H-azepine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CB1 modulator; preparation of imidazolecarboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)

RN 505073-33-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



L3 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:164961 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 142:411290
 TITLE: Synthesis, Structure-Activity Relationships at the GABAA Receptor in Rat Brain, and Differential Electrophysiological Profile at the Recombinant Human GABAA Receptor of a Series of Substituted 1,2-Diphenylimidazoles

AUTHOR(S): Asproni, Battistina; Talani, Giuseppe; Busonero, Fabio; Pau, Amedeo; Sanna, Sebastiano; Cerri, Riccardo; Mascia, Maria Paola; Sanna, Enrico; Biggio, Giovanni

CORPORATE SOURCE: Dipartimento Farmaco Chimico Tossicologico, Universita di Sassari, Sassari, Italy

SOURCE: Journal of Medicinal Chemistry (2005), 48(7), 2638-2645
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:411290

GI



AB A series of new 1,2-diphenylimidazole derivs. I (R = H, Me, CO2H, CO2Me, CO2Et, CO2Pr, CONEt2, etc.; X = H, F, Cl, Br, iodo, Me, OMe, NO2, NH2, NHAc; X1 = H, 3-Cl, 4-Cl, 4-F, 3,4-CL2, 2,4-CL2) were synthesized and evaluated for their ability to potentiate γ -aminobutyric acid (GABA)-evoked currents in *Xenopus laevis* oocytes expressing recombinant human GABAA receptors. Many of these compds. enhanced GABA action with potencies (EC50 = 0.19-19 μ M) and efficacies (maximal efficacies of up to 640%) similar to or greater than those of anesthetics such as etomidate, propofol, and alphaxalone. Structure-activity relationship anal. revealed that the presence of an ester moiety in the imidazole ring was required for full agonist properties, while modifications made in the Ph rings affected potency and efficacy, with II (X = Br) showing the highest potency. These compds. potentiated the [3H]GABA binding to rat brain membranes, suggesting a site of interaction different from that of GABA. As for etomidate, mutation of asparagine-265 in the β 2 subunit of the GABAA receptor into serine reduced the ability of derivative II (X = Cl) to modulate the GABA function.


IT 850339-41-2F

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and GABA-A receptor binding structure-activity of substituted diphenylimidazoles)


RN 850339-41-2 CAPLUS

CN Methanone, [2-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:130306 CAPLUS Full-text
 DOCUMENT NUMBER: 142:392336
 TITLE: Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists
 AUTHOR(S): Plummer, Christopher W.; Finke, Paul E.; Mills, Sander G.; Wang, Junying; Tong, Xinchun; Doss, George A.; Fong, Tung M.; Lao, Julie Z.; Schaeffer, Marie-Therese; Chen, Jing; Shen, Chun-Pyn; Stribling, D. Sloan; Shearman, Lauren P.; Strack, Alison M.; Van der Ploeg, Lex H. T.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1441-1446
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:392336
 GI




AB Structure-activity relationship studies directed toward the optimization of 4,5-diarylimidazole-2-carboxamide analogs as human CB1 receptor inverse agonists resulted in the discovery of the two amide derivs. I (X = N, CH) (hCB1 IC50 = 6.1 and 4.0 nM). I also demonstrated efficacy in overnight feeding studies in the rat for reduction in both food intake and overall body weight
 IT 489446-71-1P 489446-86-8P 489447-12-3P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, human cannabinoid receptor type 1 binding affinity, and SAR of diarylimidazolecarboxamides and -oxazolecarboxamides starting from arylaldehydes or ketones and using heterocyclization and amidation as the key steps)


RN 489446-71-1 CAPLUS

CN Methanone, (1-methyl-4,5-diphenyl-1H-imidazol-2-yl)-1-piperidinyl- (CA INDEX NAME)




RN 489446-86-8 CAPLUS

CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



RN 489447-12-3 CAPLUS


CN Methanone, [4,5-bis(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:99481 CAPLUS Full-text
 DOCUMENT NUMBER: 142:198075
 TITLE: Preparation of imidazole derivatives as cannabinoid receptor ligands
 INVENTOR(S): Carpino, Philip A.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009974	A1	20050203	WO 2004-IB2442	20040719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050026983	A1	20050203	US 2004-893011	20040715
PRIORITY APPLN. INFO.:			US 2003-491013P	P 20030730
OTHER SOURCE(S):			CASREACT 142:198075; MARPAT 142:198075	
GI				




AB Title compds. I [wherein R₁, R₂ = (un)substituted (hetero)aryl; R_{3a} = H or alkyl; R_{3b} = H, (un)substituted (cyclo)alkyl, heterocyclyl or (hetero)aryl; n = 0-2; L = CH₂ or C(O); R₄ = (un)substituted amino or hydrazino; or pharmaceutically acceptable salts or solvates or hydrates thereof or the salts] were prepared as cannabinoid receptor ligands. For example, imidazolecarboxamide II was synthesized via the coupling of the corresponding N-Boc protected acid (preparation given) with piperidine in the presence of EDC-HOBT followed by deprotection with HCl/EtOH. Three tested compds., including II, were found to have binding activities from 1-10 nM against cannabinoid receptor CB₁. Other biol. properties were also assayed (no data).

The invented compds. are useful in the treatment of diseases linked to the activation of the cannabinoid receptors, such as obesity.

IT 837365-15-8P, [2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-((isopropylamino)methyl)-1H-imidazol-4-yl]piperidin-1-ylmethanone
 837365-16-9P, [2-(2-Chlorophenyl)-1-(4-chlorophenyl)-5-[(isopropylamino)methyl]-1H-imidazol-4-yl]pyrrolidin-1-ylmethanone
 837365-17-0P, [1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-5-[(isopropylamino)methyl]-1H-imidazol-4-yl]piperidin-1-ylmethanone
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (ligand; preparation of imidazolecarboxamides as cannabinoid receptor ligands)


RN 837365-15-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-[[1-(methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 837365-16-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-[[1-(methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-pyrrolidinyl- (CA INDEX NAME)




RN 837365-17-0 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-[[1-(methylethyl)amino]methyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



IT 837365-18-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (ligand; preparation of imidazolecarboxamides as cannabinoid receptor
 ligands)
 RN 837365-18-1 CAPLUS
 CN Carbamic acid, [[2-(2-chlorophenyl)-1-(4-chlorophenyl)-4-(1-
 piperidinylcarbonyl)-1H-imidazol-5-yl]methyl](1-methylethyl)-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:996115 CAPLUS Full-text
 DOCUMENT NUMBER: 141:410930
 TITLE: Preparation of imidazole derivatives as cyclooxygenase
 (COX) inhibitors
 INVENTOR(S): Takahashi, Fumie; Terasaka, Tadashi; Morita, Masataka;
 Konishi, Nobukiyo; Nakamura, Katsuya
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099130	A2	20041118	WO 2004-JP5987	20040426
WO 2004099130	A3	20050127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,


GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

CA 2524889	A1	20041118	CA 2004-2524889	20040426
EP 1620406	A2	20060201	EP 2004-729517	20040426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1784386	A	20060607	CN 2004-80012372	20040426
JP 2006525320	T	20061109	JP 2006-507723	20040426
MX 2005PA11855	A	20060217	MX 2005-PA11855	20051104
US 20070043084	A1	20070222	US 2005-555656	20051104
IN 2005CN03322	A	20070601	IN 2005-CN3322	20051208
PRIORITY APPLN. INFO.:				
			AU 2003-902208	A 20030508
			AU 2003-903861	A 20030724
			AU 2003-904068	A 20030801
			WO 2004-JP5987	W 20040426

OTHER SOURCE(S): MARPAT 141:410930
 GI



I



II

AB Title compds. I [wherein R1 = (un)substituted (cyclo)alkyl, carbamoyl, cyano, formyl, carboxy or carbonyl; R2 = hydroxy, halo, cyano, or alkoxy; R3 = alkoxy or amino; X, Y = CH or N; et al., or pharmaceutically acceptable salts thereof], were prepared as cyclooxygenase (COX) inhibitors. E.g., addition reaction of p-anisidine with 6-methoxy-3-pyridinecarbonitrile using NaHMDS as base (58.4%) followed by cyclization with 3-bromo-1,1,1-trifluoro-2-propanone (21.5%) gave imidazole II. Tested compds. I, including II, showed effective analgesic activity (coefficient >1.5) on adjuvant arthritis at a dose of 3.2 mg/kg, and selectively inhibited COX-I with IC50 (μM) of <0.01 against COX-I (vs. ≥ 0.1 against COX-II). I are therefore useful for the treatment and/or prevention of the diseases associated with COX, such as inflammation, pain, collagen, autoimmune, immunity, thrombosis, cancer and neurodegenerative diseases.


IT 726196-57-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)

RN 726196-57-2 CAPLUS

CN Methanone, [2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]-1H-imidazol-4-

yl]-1-piperidinyl- (CA INDEX NAME)




IT 726196-58-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(COX inhibitor; preparation of imidazoles as cyclooxygenase (COX) inhibitors)

RN 726196-58-3 CAPLUS

CN Methanone, [1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:927195 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 141:395556

TITLE: Preparation ofazole compounds as platelet aggregation inhibitors

INVENTOR(S): Okayama, Toru; Uoto, Kouichi; Ishiyama, Takashi; Kanaya, Naoaki; Kimura, Youichi; Ishihara, Hiroaki; Watanabe, Toshiyuki; Fujii, Kunihiro

PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan

SOURCE: PCT Int. Appl., 223 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094407	A1	20041104	WO 2004-JP5605	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				


CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG
 AU 2004232577 A1 20041104 AU 2004-232577 20040420
 CA 2522536 A1 20041104 CA 2004-2522536 20040420
 EP 1621537 A1 20060201 EP 2004-728462 20040420
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 CN 1774435 A 20060517 CN 2004-80010326 20040420
 NO 2005004854 A 20051115 NO 2005-4854 20051020
 MX 2005PA11276 A 20060124 MX 2005-PA11276 20051020
 US 20060189591 A1 20060824 US 2005-553982 20051020
 PRIORITY APPLN. INFO.: JP 2003-115204 A 20030421
 JP 2004-42859 A 20040219
 WO 2004-JP5605 W 20040420
 OTHER SOURCE(S): MARPAT 141:395556
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. Q-X-Y (I) [Q = II, etc.; Ar1, Ar2 = (un)substituted 6-membered aromatic heterocycles; (un)substituted phenyl; R2 = H, halo, etc.; X = carbonyl, thiocarbonyl; Y = III; A = 4-7 membered ring, further detail on said ring is given; R1 = OH, etc.] were prepared For example, EDCI-mediated coupling of 2-(6-methoxy-3-pyridyl)-1-(2-pyridyl)-1H-imidazole-4-carboxylic acid with (3R)-fluoropiperidine hydrochloride afforded compound IV in 44% yield. In platelet aggregation inhibition assays, the IC50 value of compound IV was 0.11 μ M. Of note, compds. I inhibit neither COX-1 nor COX-2. Disclosed compds. I are claimed useful for the treatment of ischemia.
 IT 787562-41-8P 787562-52-1P 787562-54-3P
 787562-56-5P 787562-63-4P 787562-66-7P
 787564-53-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation ofazole compds. as platelet aggregation inhibitors for treatment of ischemia)
 RN 787562-41-8 CAPLUS
 CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-52-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-3-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 787562-54-3 CAPLUS
 CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (2-methyl-1-piperazinyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 787562-53-2
 CMF C21 H23 N5 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 787562-56-5 CAPLUS
 CN Methanone, (3,4-dimethyl-1-piperazinyl) [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-63-4 CAPLUS

CN Methanone, (4,5-diphenyl-2-oxazolyl)(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-66-7 CAPLUS

CN Methanone, [5-(4-fluorophenyl)-4-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787564-53-8 CAPLUS

CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




IT 787562-38-3P 787562-40-7P 787562-42-9P
 787562-43-0P 787562-45-2P 787562-46-3P
 787562-47-4P 787562-48-5P 787562-49-6P
 787562-50-9P 787562-51-0P 787562-55-4P
 787562-57-6P 787562-58-7P 787562-59-8P
 787562-60-1P 787562-61-2P 787562-62-3P
 787562-64-5P 787562-65-6P 787562-67-8P
 787562-68-9P 787562-69-0P 787562-70-3P
 787562-71-4P 787562-72-5P 787562-73-6P
 787562-74-7P 787562-75-8P 787562-76-9P
 787562-77-0P 787562-78-1P 787562-80-5P
 787562-81-6P 787562-82-7P 787562-83-8P
 787562-84-9P 787562-85-0P 787562-86-1P
 787562-87-2P 787562-88-3P 787562-89-4P
 787562-90-7P 787562-91-8P 787562-92-9P
 787562-93-0P 787562-94-1P 787562-95-2P
 787562-96-3P 787562-97-4P 787562-98-5P
 787562-99-6P 787563-00-2P 787563-01-3P
 787563-02-4P 787563-03-5P 787563-04-6P
 787563-05-7P 787563-06-8P 787563-07-9P
 787563-08-0P 787563-09-1P 787563-10-4P
 787563-11-5P 787563-12-6P 787563-13-7P
 787563-14-8P 787563-15-9P 787563-16-0P
 787563-17-1P 787563-18-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of azole compds. as platelet aggregation inhibitors for
 treatment of ischemia)


RN 787562-38-3 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[2-phenyl-1-(3-pyridinyl)-1H-imidazol-4-
 yl]- (CA INDEX NAME)




RN 787562-40-7 CAPLUS

CN Methanone, (5-methyl-1,2-diphenyl-1H-imidazol-4-yl)(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-42-9 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-43-0 CAPLUS

CN Methanone, [1-(4-fluorophenyl)-2-(6-methoxy-3-pyridinyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-45-2 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]-4-morpholinyl- (CA INDEX NAME)




RN 787562-46-3 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (2,2,4-trimethyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-47-4 CAPLUS

CN Methanone, [3-(dimethylamino)-1-azetidiny] [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-48-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 787562-49-6 CAPLUS

CN Methanone, (4-methyl-1-piperazinyl)[2-(6-methyl-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-50-9 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-51-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-, phenylmethyl ester (CA INDEX NAME)




RN 787562-55-4 CAPLUS

CN Methanone, (2,4-dimethyl-1-piperazinyl)[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-57-6 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 787562-58-7 CAPLUS

CN Methanethione, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787562-59-8 CAPLUS

CN Methanone, [1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]-4-morpholinyl- (CA INDEX NAME)




RN 787562-60-1 CAPLUS

CN Methanone, (hexahydro-4-methyl-1H-1,4-diazepin-1-yl) [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787562-61-2 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (tetrahydro-3-methyl-1(2H)-pyrimidinyl)- (CA INDEX NAME)




RN 787562-62-3 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl] (tetrahydro-2-methyl-1(2H)-pyridazinyl)- (CA INDEX NAME)



RN 787562-64-5 CAPLUS


CN Methanone, (4,5-diphenyl-2-oxazolyl) (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-65-6 CAPLUS

CN Methanone, [4-(6-methoxy-3-pyridinyl)-5-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-67-8 CAPLUS


CN Methanone, [5-(4-fluorophenyl)-4-(3-pyridinyl)-2-oxazolyl](4-methyl-1-piperazinyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 787562-68-9 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl](tetrahydro-1,4-oxazepin-4(5H)-yl)- (CA INDEX NAME)




RN 787562-69-0 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 787562-70-3 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)




RN 787562-71-4 CAPLUS

CN 2-Piperazinone, 4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 787562-72-5 CAPLUS

CN 2-Piperazinone, 1-methyl-4-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 787562-73-6 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-74-7 CAPLUS


CN Methanone, [5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-75-8 CAPLUS

CN Methanone, (4-cyclopropyl-1-piperazinyl) [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-76-9 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-phenyl-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-77-0 CAPLUS


CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-78-1 CAPLUS


CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl] (4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-80-5 CAPLUS

CN Methanone, [3-(dimethylamino)-1-azetidiny][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-81-6 CAPLUS

CN Methanone, [5-(3-fluoro-4-methylphenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-82-7 CAPLUS


CN Methanone, [1-(4-methylphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-83-8 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 787562-84-9 CAPLUS


CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-85-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-4,7-diazaspiro[2.5]oct-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)




RN 787562-86-1 CAPLUS

CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-87-2 CAPLUS


CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-88-3 CAPLUS

CN 2-Azetidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)



RN 787562-89-4 CAPLUS


CN Methanone, [2-[(dimethylamino)methyl]-1-azetidiny][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 787562-90-7 CAPLUS

CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidiny] [1-(4-methoxyphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787562-91-8 CAPLUS

CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)



RN 787562-92-9 CAPLUS


CN 2-Piperazinone, 4-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-93-0 CAPLUS


CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-4-

morpholinyl- (CA INDEX NAME)




RN 787562-94-1 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)




RN 787562-95-2 CAPLUS

CN 2-Piperazinone, 4-[[2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-96-3 CAPLUS


CN 2-Piperazinone, 4-[[1-(4-fluorophenyl)-2-(6-methoxy-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-97-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 787562-98-5 CAPLUS


CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 787562-99-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-phenyl-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-00-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[2-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-01-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[1-(4-methylphenyl)-2-(6-methyl-3-pyridinyl)-1H-imidazol-4-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-02-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 787563-03-5 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 787563-04-6 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-05-7 CAPLUS

CN Methanone, (4-fluoro-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-06-8 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 787563-07-9 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787563-08-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 787563-09-1 CAPLUS


CN Methanone, [2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787563-10-4 CAPLUS


CN Methanone, [(3S)-3-fluoro-1-pyrrolidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787563-11-5 CAPLUS

CN Methanone, [4-(fluoromethyl)-1-piperidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)



RN 787563-12-6 CAPLUS


CN Methanone, (4,4-difluoro-1-piperidinyl)[5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-13-7 CAPLUS


CN Methanone, [(3R)-3-fluoro-1-piperidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 787563-14-8 CAPLUS

CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 787563-15-9 CAPLUS

CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




RN 787563-16-0 CAPLUS

CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-17-1 CAPLUS


CN Methanone, [5-(5-chloro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



RN 787563-18-2 CAPLUS

CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][2-(6-methoxy-3-pyridinyl)-1-(2-pyridinyl)-1H-imidazol-4-yl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:790826 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 142:219202

TITLE: Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists

AUTHOR(S): Lange, Jos H. M.; van Stuivenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.

CORPORATE SOURCE: Research Laboratories, Solvay Pharmaceuticals, Weesp, 1381 CP, Neth.

SOURCE: Journal of Medicinal Chemistry (2005), 48(6), 1823-1838
CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219202

GI




I

AB Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant. A number of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays. The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class. Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model. Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant. A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.


IT 796875-33-7P 796875-35-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidazole, thiazole, and triazole analogs of rimonabant as potent and selective CB1 cannabinoid receptor antagonists)

RN 796875-33-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl](4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 796875-35-9 CAPLUS
 CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl] (3,4-dihydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:633918 CAPLUS Full-text

DOCUMENT NUMBER: 141:174163

TITLE: Oxazole derivatives as inhibitors of cyclooxygenase, especially COX-I, and their preparation, pharmaceutical compositions, medicaments, and use as analgesics, etc.

INVENTOR(S): Yamamoto, Hirofumi; Ishida, Junya; Tanabe, Daisuke; Satoh, Shigeki; Sawada, Yuki; Ohkawa, Takehiko; Imamura, Kenichiro; Nakamura, Katsuya

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 257 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004065374	A1	20040805	WO 2004-JP339	20040116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
CA 2513295	A1	20040805	CA 2004-2513295	20040116
US 20040157891	A1	20040812	US 2004-758253	20040116

EP 1583749	A1	20051012	EP 2004-702816	20040116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006517535	T	20060727	JP 2006-500393	20040116
CN 1835934	A	20060920	CN 2004-80002095	20040116
MX 2005PA07463	A	20060614	MX 2005-PA7463	20050711
IN 2005CN01899	A	20070706	IN 2005-CN1899	20050811
PRIORITY APPLN. INFO.:			AU 2003-900207	A 20030117
			AU 2003-901873	A 20030331
			WO 2004-JP339	W 20040116

OTHER SOURCE(S): MARPAT 141:174163


GI




AB Title compds. I are disclosed [wherein: R1 is H, (un)substituted alk(en/yn)yl, (hetero)aryl, (hetero)cycloalkyl, (un)substituted alk(en/yn)yloxy, (un)substituted amino, (un)substituted carbamoyl, cyano, carboxy, OH, SH, halo, etc.; R2 is alkyl, heterocyclyl, alkoxy, cyano; R3, R4 is alkylene, alkenylene, bond; R5 is H, alkyl, (hetero)aryl, alkoxy, acyloxy, OH or derivs., cyano, azido, (un)substituted amino, etc.; X is O, S, SO, or SO2; Y is CH or N; n is 0 or 1; or pharmaceutically acceptable salts thereof]. Compds. I have cyclooxxygenase (COX) inhibitory activity, especially against the isoenzyme COX-I. Claimed uses include treatment and prevention of inflammation, pain, collagen diseases, autoimmune diseases, various immunity diseases, thrombosis, cancer, and neurodegenerative diseases, in humans and animals. Over 300 compds. I were prepared in examples, as well as many acyclic intermediates to the oxazole nucleus. Many compds. I were also used as intermediates to other compds. I. Thus, 1-[4-(benzyloxy)phenyl]-2-(4-methoxyphenyl)ethanone underwent a sequence of α -bromination, substitution of bromo by potassium phthalimide, hydrazinolysis of the imide, amidation of the resultant amine with CHF₂CO₂H, and cyclocondensation using PPh₃, I₂, and Et₃N, to give invention compound II [R = PhCH₂]. This compound underwent a sequence of debenzoylation, etherification with BrCH₂CO₂Et, and ester reduction with LiAlH₄, to give invention compound II [R = HOCH₂CH₂] (III), a preferred compound. In an adjuvant arthritis test in rats, III had an ED of 3.2 mg/kg.

In human whole blood assays, III had IC50 values of < 0.01 μ M for COX-I and > 0.1 μ M for COX-II, showing selectivity for the former.


IT 735266-75-8P, 1-[[5-[4-(Benzyloxy)phenyl]-4-(4-methoxyphenyl)-1,3-oxazol-2-yl]carbonyl]piperidine 735266-76-9P, 4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenol 735267-21-7P, 5-[5-[4-(Benzyloxy)phenyl]-2-(1-piperidinylcarbonyl)-1,3-oxazol-4-yl]-2-methoxypyridine 735267-22-8P, 4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenol 735267-24-0P, tert-Butyl [2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]carbamate 735267-41-1P, [2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride 735267-59-1P, tert-Butyl [2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]carbamate 735267-60-4P, [2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]amine hydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of diaryl-substituted oxazole derivs. as selective COX-I inhibitors for use as analgesics)
 RN 735266-75-8 CAPLUS
 CN Methanone, [4-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)



RN 735266-76-9 CAPLUS
 CN Methanone, [5-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-21-7 CAPLUS
 CN Methanone, [4-(6-methoxy-3-pyridinyl)-5-[4-(phenylmethoxy)phenyl]-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-22-8 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-24-0 CAPLUS

CN Carbamic acid, [2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 735267-41-1 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl-, hydrochloride (1:?) (CA INDEX NAME)




RN 735267-59-1 CAPLUS

CN Carbamic acid, [2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 735267-60-4 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl-, hydrochloride (1:?) (CA INDEX NAME)




IT 735266-77-0P, 2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethanol 735267-23-9P, 2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethanol 735267-42-2P, N-[2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-

yl]phenoxy]ethyl]methanesulfonamide 735267-43-3P,
 N-[2-[4-[4-(6-Methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]urea 735267-61-5P, N-[2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]urea 735267-62-6P, N-[2-[4-[4-(4-Methoxyphenyl)-2-(1-piperidinylcarbonyl)-1,3-oxazol-5-yl]phenoxy]ethyl]methanesulfonamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diaryl-substituted oxazole derivs. as selective COX-I inhibitors for use as analgesics)


RN 735266-77-0 CAPLUS

CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-4-(4-methoxyphenyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-23-9 CAPLUS

CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-4-(6-methoxy-3-pyridinyl)-2-oxazolyl]-1-piperidinyl- (CA INDEX NAME)




RN 735267-42-2 CAPLUS

CN Methanesulfonamide, N-[2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)




RN 735267-43-3 CAPLUS

CN Urea, N-[2-[4-[4-(6-methoxy-3-pyridinyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)




RN 735267-61-5 CAPLUS

CN Urea, N-[2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)



RN 735267-62-6 CAPLUS


CN Methanesulfonamide, N-[2-[4-[4-(4-methoxyphenyl)-2-(1-piperidinylcarbonyl)-5-oxazolyl]phenoxy]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:589415 CAPLUS Full-text
 DOCUMENT NUMBER: 141:140441
 TITLE: Preparation of imidazole and triazole derivatives useful as selective COX-1 inhibitors
 INVENTOR(S): Takahashi, Fumie; Nakagawa, Toshiya; Matsushima, Yuji; Nakamura, Katsuya
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060367	A1	20040722	WO 2003-JP15921	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003288746	A1	20040729	AU 2003-288746	20031212
PRIORITY APPLN. INFO.:			AU 2002-953602	A 20021230
			AU 2003-901804	A 20030415
			AU 2003-903928	A 20030728
			WO 2003-JP15921	W 20031212
OTHER SOURCE(S):			MARPAT 141:140441	
GI				



AB Imidazole and triazole derivs. were prepared for use as selective COX-1 inhibitors for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodegenerative diseases. Thus, 4-PhCH₂OCH₂CH₂C₆H₄NH₂ was treated with 4-MeOC₆H₄CN to give 4-PhCH₂OCH₂CH₂C₆H₄NHC(:NH)C₆H₄OMe-4 which was cyclized with BrCH₂COCF₃ and debenzylated to give the imidazole I. I had IC₅₀ for COX-1 inhibition of < 0.01 and an analgesic coefficient relative to controls of > 1.5.


IT 726194-47-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)

RN 726194-47-4 CAPLUS

CN Methanone, [1-[4-(2-hydroxyethoxy)phenyl]-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




IT 726196-57-2P 726196-58-3P 726197-06-4P
726197-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)


RN 726196-57-2 CAPLUS

CN Methanone, [2-(4-methoxyphenyl)-1-[4-(phenylmethoxy)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726196-58-3 CAPLUS

CN Methanone, [1-(4-hydroxyphenyl)-2-(4-methoxyphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726197-06-4 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




RN 726197-20-2 CAPLUS


CN Methanone, [1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)




IT 726195-26-2P 726195-46-6P 726195-54-6P
 726195-64-8P 726195-74-0P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)
 RN 726195-26-2 CAPLUS
 CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 726195-46-6 CAPLUS
 CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 726195-54-6 CAPLUS
 CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)




RN 726195-64-8 CAPLUS

CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 726195-74-0 CAPLUS

CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2004:272442 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 140:303680

TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands

INVENTOR(S): Lange, Josephus H. m.; Kruse, Cornelis G.; McCreary, Andrew C.; Van Stuivenberg, Herman H.
 PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026301	A1	20040401	WO 2003-EP50628	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1402891	A1	20040331	EP 2002-78966	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040106614	A1	20040603	US 2003-662477	20030916
US 7319110	B2	20080115		
CA 2491394	A1	20040401	CA 2003-2491394	20030917
AU 2003299024	A1	20040408	AU 2003-299024	20030917
AU 2003299024	B2	20080306		
BR 2003012020	A	20050322	BR 2003-12020	20030917
EP 1542678	A1	20050622	EP 2003-797318	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006501275	T	20060112	JP 2004-537155	20030917
RU 2325382	C2	20080527	RU 2005-103244	20030917
IN 2004CN03228	A	20060303	IN 2004-CN3228	20041213
ZA 2005000133	A	20051101	ZA 2005-133	20050106
MX 2005PA02862	A	20050527	MX 2005-PA2862	20050315
NO 2005001870	A	20050603	NO 2005-1870	20050418
HK 1078796	A1	20071012	HK 2005-110963	20051201
PRIORITY APPLN. INFO.:			EP 2002-78966	A 20020919
			WO 2003-EP50628	W 20030917
OTHER SOURCE(S):			MARPAT 140:303680	
GI				




AB The title compds. [I; R, R1 = Ph, naphthyl, thienyl, pyridyl, etc.; R2 = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl] which are potent cannabinoid-CB1 receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of disorders involving cannabinoid neurotransmission, were prepared E.g., a 4-step synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4-triazole-3-carboxamide hydrochloride, starting from di-Me aminomalonate.HCl and 4-chlorobenzoyl chloride, was given. The compds. I were tested for in vitro affinity and in vitro antagonism at human cannabinoid-CB1 receptors. The biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound I is claimed.

IT 676457-12-8P 676457-31-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands)


RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:153570 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 140:391240

TITLE: Potent imidazole and triazole CB1 receptor antagonists related to SR141716
 AUTHOR(S): Dyck, Brian; Goodfellow, Val S.; Phillips, Teresa; Grey, Jonathan; Haddach, Mustapha; Rowbottom, Martin; Naeve, Gregory S.; Brown, Brock; Saunders, John
 CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1151-1154
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:391240
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-1H-1,2,4-triazole-3-carboxamide (II) and 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).
 IT 683208-86-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of imidazolecarboxamides and triazolecarboxamides related to SR 141716 and study of their activity as cannabinoid CB1 receptor antagonists)
 RN 683208-86-8 CAPLUS
 CN Methanone, [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:376829 CAPLUS Full-text

DOCUMENT NUMBER: 138:385424

TITLE: Imidazole-4-carboxamide derivatives, and their preparation and use for treatment of obesity

INVENTOR(S): Smith, Roger A.; O'Connor, Stephen J.; Wirtz, Stephan-Nicholas; Wong, Wai C.; Choi, Soongyu; Kluender, Harold C. E.; Su, Ning; Wang, Gan; Achebe, Furahi; Ying, Shihong

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA

SOURCE: PCT Int. Appl., 225 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2003040107	A1	20030515	WO 2002-US30545	20020924
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2459745	A1	20030515	CA 2002-2459745	20020924
AU 2002343423	A1	20030519	AU 2002-343423	20020924
US 20040063691	A1	20040401	US 2002-255049	20020924
US 6960601	B2	20051101		
EP 1432691	A1	20040630	EP 2002-780365	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012986	A	20040817	BR 2002-12986	20020924
HU 2004002376	A2	20050228	HU 2004-2376	20020924
CN 1599724	A	20050323	CN 2002-818693	20020924
JP 2005508384	T	20050331	JP 2003-542153	20020924
NZ 531841	A	20050930	NZ 2002-531841	20020924
CN 1865248	A	20061122	CN 2006-10091513	20020924
MX 2004PA02037	A	20040607	MX 2004-PA2037	20040303
IN 2004DN00612	A	20070112	IN 2004-DN612	20040310
NO 2004001216	A	20040505	NO 2004-1216	20040323
ZA 2004003035	A	20050421	ZA 2004-3035	20040421
US 20050256167	A1	20051117	US 2005-133751	20050520
PRIORITY APPLN. INFO.:			US 2001-324473P	P 20010924
			CN 2002-818693	A3 20020924
			US 2002-255049	A3 20020924
			WO 2002-US30545	W 20020924

OTHER SOURCE(S): MARPAT 138:385424

GI



AB The invention relates to imidazole derivs. I, which have been found to suppress appetite and induce weight loss [wherein: R1, R2 = alkyl, (un)substituted Ph, alkyl, naphthyl, benzyl, (un)saturated or aromatic heterocyclyl; R3 = H, alkyl, benzyl, Cl, or Br; X = (a) CONR4R5 or (b) CONHSO2R10; (a) R4 = H or alkyl; R5 = (un)substituted alkyl, bicycloalkyl, benzyl, phenethyl, piperidinyl or pyrrolidinyl, NR6R7, etc.; or NR4R5 = (un)substituted (un)saturated heterocyclyl; R6 = H or alkyl; R7 = alkyl or (un)substituted Ph; or NR6R7 = (un)substituted (un)saturated heterocyclyl; or (b) R10 = (un)substituted alkyl, benzocyclohexyl, or benzocyclopentyl; including pharmaceutical salts and esters]. The invention also provides methods for synthesis of the compds., pharmaceutical compns. comprising them, and methods of using such compns. for inducing weight loss and treating obesity and obesity-related disorders. Such disorders include dyslipidemia, hypertriglyceridemia, hypertension, diabetes, syndrome X, atherosclerotic disease, cardiovascular disease, cerebrovascular disease, peripheral vessel disease, cholesterol gallstones, cancer, menstrual abnormalities, infertility, polycystic ovaries, osteoarthritis, and sleep apnea. I are also claimed for use in regulating appetite, treating bulimia, treating CNS disorders, treating cognition and memory disorders, and treating substance or behavioral addiction. I may also be administered or formed into pharmaceutical compns. in combination with other agents for similar treatments, e.g., antiobesity agents, hypolipidemics, and antihypertensives. Approx. 50 synthetic examples of both invention compds. and intermediates are given, and several tables of compds. I (480 total compds.) are provided. For instance, 2-chloro-N-(4-chlorophenyl)benzenecarboximidamide was cyclized with Et 3-bromo-2-oxopentanoate in the presence of K2CO3 to give an imidazole-4-carboxylate ester, which reacted with 1-aminopiperidine in the presence of AlMe3 to give title compound II. In the fasted-refed acute feeding assay in rats, invention compound III at 10 mg/kg orally reduced food consumption by 31-53% vs. control.

IT 527368-74-7P 527368-79-2P 527368-89-4P
527380-29-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of imidazolecarboxamide derivs. as antiobesity agents)

RN 527368-74-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]-4-

thiomorpholinyl- (CA INDEX NAME)




RN 527368-79-2 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527368-89-4 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)



RN 527380-29-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl](4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




IT 527368-13-4P 527368-24-7P 527368-29-2P
527368-32-7P 527368-37-2P 527368-42-9P
527368-46-3P 527368-51-0P 527368-61-2P
527368-84-9P 527368-98-5P 527369-08-0P
527369-13-7P 527371-67-1P 527371-72-8P
527371-76-2P 527371-81-9P 527371-87-5P
527371-91-1P 527371-96-6P 527372-01-6P
527372-06-1P 527372-11-8P 527372-16-3P
527372-21-0P 527372-26-5P 527372-32-3P
527372-35-6P 527372-41-4P 527372-46-9P
527372-49-2P 527372-54-9P 527372-59-4P
527372-63-0P 527372-68-5P 527372-73-2P
527372-77-6P 527372-82-3P 527372-87-8P
527372-92-5P 527372-97-0P 527373-02-0P
527373-06-4P 527373-11-1P 527373-16-6P
527373-20-2P 527373-26-8P 527373-32-6P
527373-36-0P 527373-41-7P 527373-47-3P
527373-52-0P 527373-57-5P 527375-32-2P
527375-37-7P 527375-42-4P 527377-14-6P
527377-19-1P 527377-25-9P 527377-30-6P
527377-34-0P 527377-39-5P 527377-44-2P
527377-49-7P 527377-54-4P 527377-59-9P
527377-63-5P 527377-68-0P 527377-73-7P
527377-78-2P 527377-83-9P 527377-87-3P
527377-92-0P 527377-97-5P 527378-02-5P
527378-07-0P 527378-12-7P 527378-18-3P
527378-22-9P 527378-27-4P 527378-32-1P
527378-36-5P 527378-40-1P 527378-44-5P
527378-48-9P 527378-52-5P 527378-56-9P
527378-60-5P 527378-68-3P 527378-73-0P
527378-78-5P 527378-83-2P 527378-88-7P
527378-93-4P 527378-98-9P 527379-04-0P
527379-08-4P 527379-13-1P 527379-18-6P
527379-22-2P 527379-27-7P 527379-32-4P
527379-37-9P 527379-42-6P 527379-48-2P
527379-52-8P 527379-58-4P 527379-63-1P
527379-67-5P 527379-70-0P 527379-75-5P
527379-80-2P 527379-85-7P 527379-90-4P
527379-95-9P 527380-00-3P 527380-05-8P
527380-09-2P 527380-14-9P 527380-19-4P
527380-24-1P 527380-34-3P 527380-38-7P
527380-43-4P 527380-48-9P 527380-53-6P
527380-58-1P 527384-14-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazolecarboxamide derivs. as antiobesity agents)


RN 527368-13-4 CAPLUS

CN Methanone, [2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527368-24-7 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527368-29-2 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-32-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-37-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2-methylphenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-42-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-46-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (3,6-dihydro-4-phenyl-1(2H)-pyridinyl)- (CA INDEX NAME)




RN 527368-51-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(hydroxymethyl)-1-piperidiny]- (CA INDEX NAME)



RN 527368-61-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][3-(diethylamino)-1-pyrrolidiny]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527368-84-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl](1-oxido-4-thiomorpholinyl)- (CA INDEX NAME)




RN 527368-98-5 CAPLUS

CN 4-Piperidinone, 1-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]carbonyl]- (CA INDEX NAME)




RN 527369-08-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(2,4-difluorophenyl)-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527369-13-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-5-ethyl-1-[4-(1-methylethyl)phenyl]-1H-imidazol-4-yl]-1-piperidinyl- (CA INDEX NAME)




RN 527371-67-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,3-dimethylphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-72-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2,4-difluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-76-2 CAPLUS

CN Benzonitrile, 2-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-81-9 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2-phenylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-87-5 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527371-91-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527371-96-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-01-6 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 527372-06-1 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)




RN 527372-11-8 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 527372-16-3 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl][4-(cyclohexyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-21-0 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl][4-(trifluoromethyl)phenyl]-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CRN 527372-20-9
 CMF C27 H20 Cl2 F4 N4 O




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 527372-26-5 CAPLUS
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-32-3 CAPLUS
 CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(2-pyrazinyl)-1-piperazinyl]-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 527372-31-2


CMF C25 H22 Cl2 N6 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 527372-35-6 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-41-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(6-methyl-2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)


NAME)



● HCl


RN 527372-46-9 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-49-2 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-54-9 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-59-4 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-63-0 CAPLUS


CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl][4-(4-pyridinylmethyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 527372-68-5 CAPLUS

CN Benzonitrile, 4-[4-[[1-(4-chlorophenyl)-2-(2,5-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527372-73-2 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 527372-77-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-


difluorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-82-3 CAPLUS


CN Benzonitrile, 2-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-87-8 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-92-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527372-97-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-pyridinyl)-1-piperazinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 527373-02-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-06-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-11-1 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-16-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-20-2 CAPLUS


CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-cyclopropyl-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 527373-26-8 CAPLUS

CN Benzonitrile, 4-[4-[[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]carbonyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527373-32-6 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]hexahydro-1H-1,4-diazepin-1-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-36-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[(4-fluorophenyl)methyl]-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-41-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-hydroxyphenyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-47-3 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-cyclohexyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-52-0 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-methylphenyl)-1H-imidazol-4-yl] [4-(2-hydroxyethyl)-1-piperazinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 527373-57-5 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-5-methyl-1-(4-nitrophenyl)-1H-imidazol-4-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 527375-32-2 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(3S)-3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 527375-37-7 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl](3-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 527375-42-4 CAPLUS


CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 527377-14-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(1,1-dioxidobenzo[b]thien-2-yl)-4-hydroxy-1-piperidiny]- (CA INDEX NAME)




RN 527377-19-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thiazolyl)-1-piperidiny]- (CA INDEX NAME)




RN 527377-25-9 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidiny][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-30-6 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-34-0 CAPLUS

CN Methanone, [4-(2-benzofuranyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-39-5 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl)[2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-44-2 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-49-7 CAPLUS

CN Methanone, (4-benzo[b]thien-2-yl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527377-54-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-59-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,6-dimethyl-3-pyridinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-63-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,4-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-68-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-difluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-73-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2,5-dimethoxyphenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-78-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-83-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527377-87-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-92-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527377-97-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-02-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(2-furanyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-07-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-12-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-18-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-22-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-27-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(2-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-32-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-36-5 CAPLUS

CN	Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)
----	---




RN 527378-40-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-44-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527378-52-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-56-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-60-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-68-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[3-fluoro-4-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-73-0 CAPLUS

CN Methanone, [4-(4-chloro-3-fluorophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527378-78-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-83-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-88-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527378-93-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527378-98-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-(6-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-04-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxy-3-methylphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-08-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-13-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(3-thienyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-18-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4,6-dimethyl-2-pyrimidinyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-22-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-27-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-32-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-37-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-42-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-48-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-52-8 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-58-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-63-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-ethyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-67-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-5-propyl-1H-imidazol-4-yl][4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527379-70-0 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-75-5 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-80-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[4-(methylthio)phenyl]-1-piperidinyl]- (CA INDEX NAME)




RN 527379-85-7 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(4-methyl-2-pyridinyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527379-90-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-ethyl-4-hydroxy-1-piperidinyl)- (CA INDEX NAME)




RN 527379-95-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] [4-hydroxy-4-(2-methylpropyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527380-00-3 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-05-8 CAPLUS

CN Methanone, (4-butyl-4-hydroxy-1-piperidinyl) [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-09-2 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-pentyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-14-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-19-4 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-24-1 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-34-3 CAPLUS

CN Methanone, [2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-1H-imidazol-4-yl] (4-hydroxy-4-phenyl-1-piperidinyl)- (CA INDEX NAME)




RN 527380-38-7 CAPLUS

CN Methanone, [4-(4-bromophenyl)-4-hydroxy-1-piperidinyl][2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl]- (CA INDEX NAME)




RN 527380-43-4 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)




RN 527380-48-9 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-53-6 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]- (CA INDEX NAME)




RN 527380-58-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]- (CA INDEX NAME)



RN 527384-14-1 CAPLUS

CN Methanone, [2-(2-chlorophenyl)-1-(4-chlorophenyl)-1H-imidazol-4-yl][4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:261815 CAPLUS Full-text

DOCUMENT NUMBER: 138:287674

TITLE: Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders

INVENTOR(S): Kruse, Cornelis G.; Lange, Josephus H. M.; Herremans, Arnoldus H. J.; Van Stuivenberg, Herman H.

PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027076	A2	20030403	WO 2002-EP10434	20020917
WO 2003027076	A3	20031120		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
TW 231757	B	20050501	TW 2002-91119798	20020830
CA 2457444	A1	20030403	CA 2002-2457444	20020917
AU 2002337106	A1	20030407	AU 2002-337106	20020917
AU 2002337106	B2	20070517		
EP 1438296	A2	20040721	EP 2002-772314	20020917
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012481	A	20040824	BR 2002-12481	20020917
CN 1556703	A	20041222	CN 2002-818346	20020917
JP 2005504805	T	20050217	JP 2003-530667	20020917
HU 2004002150	A2	20050228	HU 2004-2150	20020917
HU 2004002150	A3	20050829		
RU 2299200	C2	20070520	RU 2004-111979	20020917

IN 2004CN00574	A	20060113	IN 2004-CN574	20040317
ZA 2004002188	A	20050429	ZA 2004-2188	20040318
NO 2004001171	A	20040621	NO 2004-1171	20040319
US 20040235854	A1	20041125	US 2004-490019	20040319
MX 2004PA02669	A	20040618	MX 2004-PA2669	20040322
US 20050054679	A1	20050310	US 2004-912171	20040806
US 7109216	B2	20060919		
PRIORITY APPLN. INFO.:			EP 2001-203851	A 20010921
			WO 2002-EP10434	W 20020917
			US 2004-490019	A2 20040319
			US 2004-574939P	P 20040528
OTHER SOURCE(S):			MARPAT 138:287674	
GI				



I




II

AB Title compds. I [wherein R = (un)substituted Ph, thienyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; R1 = (un)substituted Ph or pyridinyl; R2 = H or (cyclo)alkyl or (cyclo)alkenyl optionally interrupted by S, O, or N; R3 = (un)substituted (cyclo)alkyl, (cyclo)alkoxy, bicycloalkyl, tricycloalkyl, or (cyclo)alkenyl optionally interrupted by N, O, or S; or R3 = pyridinyl or Ph when R4 ≠ H; or R3 = NR5R6 when R2 = H or Me; or NR2R3 = (un)substituted heterocyclyl; R4 = H, halo, CN, carbamoyl, formyl, acetyl, CF3CO, FCH2CO, EtCO, sulfamoyl, MeSO2, MeS, or (un)substituted alkyl; R5 and R6 = independently alkyl; or NR5R6 = (un)substituted heterocyclyl; and prodrugs, stereoisomers, and salts thereof] were prepared as potent cannabinoid (CB1) receptor agonists, partial agonists, or antagonists (no data). For example, reaction of 4-chloroaniline with 2,4-dichlorobenzonitrile in the presence of sodium bis(trimethylsilyl)amide in THF provided N-(4-chlorophenyl)-2,4-dichlorobenzene-carboximidine (42%). Cyclization of the carboximidine with Et 3-bromo-2-oxopropanoate in a solution of NaHCO₃ and isopropanol gave the imidazolecarboxylate (29%), which was converted to the imidazolecarbonyl chloride (no data). Amidation with 1-aminopiperidine using TEA in CH₂Cl₂ afforded II (26%). I are useful for the treatment of psychiatric and neurol. disorders, as well as and other diseases involving cannabinoid neurotransmission (no data).

IT 505073-33-6P, 1-[[1-(4-Chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-yl]carbonyl]hexahydro-1H-azepine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (CB1 modulator; preparation of imidazolecarboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurol. disorders)

RN 505073-33-6 CAPLUS
 CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-1H-imidazol-4-

yl](hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)




IT 796875-33-7

RL: PRPH (Prophetic)

(Preparation of 1H-imidazole-4-carboxamides as CB1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders)

RN 796875-33-7 CAPLUS

CN Methanone, [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-4-yl](4-hydroxy-1-piperidiny)- (CA INDEX NAME)



L3 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:76555 CAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:122647

TITLE: Preparation of 4,5-diarylimidazole derivatives as cannabinoid receptor modulators

INVENTOR(S): Finke, Paul E.; Mills, Sander G.; Plummer, Christopher W.; Shah, Shrenik K.; Truong, Quang T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.


KIND

DATE

APPLICATION NO.

DATE

WO 2003007887	A2	20030130	WO 2002-US23230	20020716
WO 2003007887	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002319627	A1	20030303	AU 2002-319627	20020716
US 20030114495	A1	20030619	US 2002-198442	20020717
US 7057051	B2	20060606		
US 20060089356	A1	20060427	US 2005-265850	20051103
PRIORITY APPLN. INFO.:			US 2001-307224P	P 20010720
			WO 2002-US23230	W 20020716
			US 2002-198442	A3 20020717
OTHER SOURCE(S):			MARPAT 138:122647	
GI				



AB The use of the title compds. [I; R1 = H, cycloalkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10 alkyl, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl; R2 = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10 alkyl, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl, ORd, NRdRe, NRdS(O)mRe; wherein alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted; Rd, Re = H, (un)substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, cycloalkyl, cycloalkyl-C1-10 alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-10, aryl, heteroaryl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl; or Rd and Re together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 addnl. heteroatoms independently selected from oxygen, sulfur and NRd; Ar1, Ar2 = (un)substituted Ph, naphthyl, thienyl, furanyl, pyrrolyl, benzothienyl, benzofuranyl, indanyl, indenyl, indolyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, or 1,4-benzodioxanyl] of the present invention as antagonists and/or inverse agonists of the cannabinoid-1 (CB1)receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor is disclosed. The invention is concerned with the use of these novel compds. to selectively antagonize the Cannabinoid-1 (CB1) receptor (no data). As such, the compds. I are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, and

schizophrenia. The compds. I are also useful for the treatment of substance abuse disorders, particularly to opiates, alc., and nicotine. The compds. I are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith. Thus, benzoin was cyclocondensed with N-methylurea in ethylene glycol at 180° for 1.5 h to give 4,5-diphenyl-1-methyl-2,3-dihydroimidazol-2-one which was heated with POC13 at 100° for 20 h to give 2-chloro-4,5-diphenyl-1-methylimidazole (II). Lithiation of II in THF with 1.6 N BuLi/hexane at -20° for 2 h followed by reaction with benzyl chloroformate at -20° for 20 min and warming the reaction mixture from -20° to room temperature over 30 min gave benzyl 4,5-diphenyl-1-methylimidazole-2-carboxylate which was hydrogenolyzed over 20% Pd/C in methanol at 40 psi for 1 h and condensed with 1-aminopiperidine containing a small percent of piperidine using ByBOP and N,N-diisopropyl-N-ethylamine in CH2Cl2 at room temperature for 20 h to give N-(piperidin-1-yl)-4,5-diphenyl-1-methylimidazole-2-carboxamide and 2-(piperidin-1-ylcarbonyl)-4,5-diphenyl-1-methylimidazole.


IT 489446-71-1P, 2-(Piperidin-1-ylcarbonyl)-4,5-diphenyl-1-methylimidazole 489446-86-3P, 2-(Piperidin-1-ylcarbonyl)-4,5-di(4-methylphenyl)-1-methylimidazole 489446-90-4P, 2-(Pyrrolidin-1-ylcarbonyl)-4,5-di(4-methylphenyl)-1-methylimidazole 489447-12-3P, 2-(Piperidin-1-ylcarbonyl)-4,5-di(4-chlorophenyl)-1-methylimidazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylimidazole derivs. as cannabinoid receptor modulators for prevention or treatment of diseases mediated by cannabinoid-1 receptor)


RN 489446-71-1 CAPLUS

CN Methanone, (1-methyl-4,5-diphenyl-1H-imidazol-2-yl)-1-piperidinyl- (CA INDEX NAME)




RN 489446-86-8 CAPLUS


CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



RN 489446-90-4 CAPLUS
CN Methanone, [1-methyl-4,5-bis(4-methylphenyl)-1H-imidazol-2-yl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 489447-12-3 CAPLUS
CN Methanone, [4,5-bis(4-chlorophenyl)-1-methyl-1H-imidazol-2-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:702237 CAPLUS [Full-text](#)
DOCUMENT NUMBER: 137:362533
TITLE: Synthesis and Pharmacological Evaluation of
1-[(1,2-Diphenyl-1H-4-imidazolyl)methyl]-4-
phenylpiperazines with Clozapine-Like Mixed Activities
at Dopamine D2, Serotonin, and GABAA Receptors
AUTHOR(S): Asproni, Battistina; Pau, Amedeo; Bitti, Mauro;
Melosu, Marilena; Cerri, Riccardo; Dazzi, Laura; Seu,
Emanuele; Maciocco, Elisabetta; Sanna, Enrico;
Busonero, Fabio; Talani, Giuseppe; Pusceddu, Luca;
Altomare, Cosimo; Trapani, Giuseppe; Biggio, Giovanni
CORPORATE SOURCE: Dipartimento Farmaco Chimico Tossicologico, Facolta di
Farmacia, Universita degli Studi di Sassari, Sassari,
07100, Italy
SOURCE: Journal of Medicinal Chemistry (2002), 45(21),
4655-4668
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:362533
AB A series of 18 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-piperazines were
designed and synthesized as possible ligands with mixed dopamine (DA)

D2/serotonin 5-HT1A affinity, with the aim of identifying novel compds. with neurochem. and pharmacol. properties similar to those of clozapine. The binding profile at D2 like, 5-HT1A, and 5-HT2A receptors of title compds. was determined. Modifications made in the Ph rings of the parent compound produced congeners endowed with a broad range of binding affinities for DA D2 like, serotonin 5-HT1A, and 5-HT2A receptors, with IC50 values ranging from 25 to >10 000 nM. As for the modification of the piperazine N4-Ph ring, the affinities for both D2 like and 5-HT1A receptors were progressively increased by introduction of ortho-methoxy and ethoxy groups. Data revealed the presence of a para-chloro substituent to be associated with a relatively high affinity and substantial selectivity for D2 like receptors, whereas the meta-chloro analog exhibited preferential affinity for 5-HT1A receptors. A quant. structure-affinity relation anal. of the measured binding data resulted in regression equations that highlighted substituent physicochem. properties modulating the binding to subtypes 1A and 2A of serotonin 5-HT receptors but not to D2 like receptors. Thus, besides an electron-withdrawing field effect and ortho substitution, which both influence binding to serotonin 5-HT receptor subtypes, though to a different extent as revealed by regression coeffs. in the multiparametric regression equations, the affinity of congeners to 5-HT1A receptors proved to be linearly correlated with volume/polarizability descriptors, whereas their affinity to 5-HT2A receptors correlated with lipophilicity consts. through a parabolic relation. 1-[(1,2-Diphenyl-1H-4-imidazolyl)methyl]-4-(2-methoxyphenyl)piperazine (I), with a D2/5-HT1A IC50 ratio of .apprx.1, was selected for a further pharmacol. study. In rats, the i.p. administration of compound I, like that of clozapine, induced an increase in the extracellular concentration of DA measured in the medial prefrontal cortex. Furthermore, I and clozapine each inhibited GABA-evoked Cl- currents at recombinant GABAA receptors expressed in Xenopus oocytes. These findings suggest that compound I may represent an interesting prototype of a novel class of drugs endowed with a neurochem. profile similar to that of atypical antipsychotics.


IT 475596-02-2P 475596-04-4P 475596-06-6P
 475596-07-7P 475596-09-9P 475596-11-3P
 475596-12-4P 475596-13-5P 475596-14-6P
 475596-15-7P 475596-16-8P 475596-17-9P
 475596-18-0P 475596-19-1P 475596-20-4P
 475596-21-5P 475596-22-6P 475596-23-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structure activity relationships of phenylpiperazines with clozapine-like mixed activities at dopamine D2, serotonin, and GABAA receptors)


RN 475596-02-2 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) (4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 475596-04-4 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-06-6 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(3-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-07-7 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(4-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-09-9 CAPLUS

CN Methanone, [4-(2-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-11-3 CAPLUS

CN Methanone, [4-(3-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-12-4 CAPLUS

CN Methanone, [4-(4-chlorophenyl)-1-piperazinyl] (1,2-diphenyl-1H-imidazol-4-yl)- (CA INDEX NAME)




RN 475596-13-5 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-14-6 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-15-7 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 475596-16-8 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-[4-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 475596-17-9 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-18-0 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(phenylmethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-19-1 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) (4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 475596-20-4 CAPLUS

CN Methanone, (1,2-diphenyl-1H-imidazol-4-yl) [4-(2-ethoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)




RN 475596-21-5 CAPLUS

CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl] (4-phenyl-1-piperazinyl)- (CA INDEX NAME)




RN 475596-22-6 CAPLUS

CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl] [4-(2-methoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 475596-23-7 CAPLUS
CN Methanone, [1,2-bis(4-fluorophenyl)-1H-imidazol-4-yl][4-(2-ethoxyphenyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:505370 CAPLUS Full-text
DOCUMENT NUMBER: 81:105370
ORIGINAL REFERENCE NO.: 81:16667a,16670a
TITLE: Heterocyclization of α -acylamino amides. III.
Properties of 5-aminoxazoles
AUTHOR(S): Clerin, Daniel; Fleury, Jean P.
CORPORATE SOURCE: Lab. Chim. Org. Gen., Ec. Super. Chim., Mulhouse, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1974),
(1-2, Pt. 2), 211-17
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French

GI For diagram(s), see printed CA Issue.


AB Treatment of 5-amino-2-aryl(or alkyl)oxazoles (I; R₂N = piperidino, 1-pyrrolidinyl, morpholino; R₁ = Ph, p-O₂NC₆H₄, p-MeC₆H₄, Me) with electrophiles gave: with H₃O⁺, R₂NCOCH₂NHCOR₁; with (CF₃CO)₂I, 4-CF₃CO derivs. of I; with PhNCO and PhNCS, 4-PhNHCO and 4-PhNCS derivs. of I; with arenediazonium salts, 4-position addition products, some of which rearranged to s-triazoles; and with sulfonyl azides, R₂SO₂N₃ (R = Me, p-MeC₆H₄), cycloaddn. products which rearranged with N elimination, then reacted with a second mol. of I to give II. When I had a Me group in the 4-position, reaction with arenediazonium salts opened the ring.

IT 53423-03-3P 53423-04-4P 53423-19-1P
53423-20-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 53423-03-3 CAPLUS


CN Morpholine, 4-[(1,5-diphenyl-1H-1,2,4-triazol-3-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 53423-04-4 CAPLUS
 CN Morpholine, 4-[[1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 53423-19-1 CAPLUS
 CN Piperidine, 1-[[5-(4-nitrophenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 53423-20-4 CAPLUS
 CN Piperidine, 1-[[1-(4-methylphenyl)-5-(4-nitrophenyl)-1H-1,2,4-triazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



ORIGINAL REFERENCE NO.: 75:23941a,23944a
 TITLE: Carboxamides and carbohydrazides of
 4,5-diphenyloxazole
 INVENTOR(S): Marchetti, Enzo
 PATENT ASSIGNEE(S): Istituto Farmacologico Serson S.p.A.
 SOURCE: Ger. Offen., 17 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2110363	A	19710916	DE 1971-2110363	19710304
CH 555846	A	19741115	CH 1971-2839	19710226
US 3869455	A	19750304	US 1971-119832	19710301
CA 949580	A1	19740618	CA 1971-106905	19710304
FR 2085675	A5	19711231	FR 1971-7751	19710305
FR 2085675	A1	19711231		
JP 50004663	B	19750222	JP 1971-11584	19710305
GB 1293702	A	19721025	GB 1971-1293702	19710419
US 3925404	A	19751209	US 1973-353675	19730423
PRIORITY APPLN. INFO.:			IT 1970-21550	A 19700305
			US 1971-119832	A3 19710301

GI For diagram(s), see printed CA Issue.


AB Title compds. (I), analgesics and central nervous system depressants, were prepared from I (R=OEt or OMe) by aminolysis or hydrazinolysis, resp., or by saponification and reaction with amines or hydrazines, resp. Thus, I (n=0, R=OEt) was refluxed 24 hr with Et₂NH to give 73% I (n=0, R=NEt₂). Similarly prepared were 15 addnl. I, e.g. (n and R given): 0, NHNMe₂; 1, NHMe; 1, morpholino; 2, NNNH₂.

IT 34015-88-8P 34015-89-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 34015-88-8 CAPLUS

CN Morpholine, 4-[(4,5-diphenyl-2-oxazolyl)carbonyl]- (8CI) (CA INDEX NAME)



RN 34015-89-9 CAPLUS

CN Pyrrolidine, 1-[(4,5-diphenyl-2-oxazolyl)carbonyl]- (8CI) (CA INDEX NAME)



L3 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1961:131227 CAPLUS Full-text

DOCUMENT NUMBER: 55:131227

ORIGINAL REFERENCE NO.: 55:24729e-i

TITLE: Action of organomagnesium compounds, piperidine, and aromatic thiols on 4-aryloxy-2-phenyloxazolin-5-ones

AUTHOR(S): Asker, Wafia; Elagroudi, Zien E.

CORPORATE SOURCE: Cairo Univ., Giza, Egypt

SOURCE: Journal of Organic Chemistry (1961), 26, 1440-3
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 55:131227

GI For diagram(s), see printed CA Issue.


AB The action of excess R'MgX on RNHN:C.N:CPh.O.CO (I) gave 1H-1,2,4-triazoles, RN.CPh:N.C(CR'2OH):N (II). Thus, adding 1 g. I (R = Ph) in 50 ml. C6H6 to PhMgBr (from 0.9 g. Mg and 9 g. PhBr in 50 ml. Et2O), refluxing the mixture 3 hrs., keeping it overnight at 25°, decomp, it with saturated aqueous NH4Cl, extracting with Et2O, evaporating the dried Et2O extract, and triturating the residue with petr. ether gave 60% II (R and R' = Ph), m. 180°. The appropriate I and R'MgBr gave the following II (R, R', % yield, and m.p. given): Ph, p-MeC6H4, 70, 189°, o-MeC6H4, Ph, 60, 152°; p-MeC6H4, Ph, 55, 145°; β-C10H7, Ph, 50, 201°. The products turned red with H2SO4. The action of piperidine on I caused a rearrangement to 1H-1,2,4-triazoles, RN.CPh:N.C(CONC5H10):N (III). Thus, adding 0.5 g. appropriate I to 0.5 ml. distilled. C5H10NH, shaking the mixture 15 min. to a clear solution, keeping it overnight at room temperature, triturating with hot petr. ether, and crystallizing the solids from dilute alc. gave the following III (R, % yield, m.p. given): Ph, 94, 193°; o-MeC6H4, 90, 127°; p-MeC6H4, 82, 141°; β-C10H7, 77, 130°. A similar rearrangement was observed from the action of aromatic thiols on I to also give 1 H-1,2,4-triazoles, RN.CPh: N.C(COSR'):N (IV). Thus, heating 1 g. I and 1 g. R'SH at 110 1.5 hrs., cooling, triturating with petr. ether, and crystallizing the residue from EtOH gave the following IV (R, R', % yield, m.p. given): Ph, Ph, 41, 146°; Ph, p-MeC6H4, 62, 195°; o-MeC6H4, p-MeC6H4, - 55, 181; p-MeC6H4, p-MeC6H4, 41, 177°; β-C10H7, p-MeC6H4, 46, 183°.

IT 111384-11-3P, Piperidine, 1-(1,5-diphenyl-1H-1,2,4-triazol-3-ylcarbonyl)- 115101-88-7P, Piperidine, 1-[5-phenyl-1-p-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 115163-48-9P, Piperidine, 1-[5-phenyl-1-o-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]-

RL: PREP (Preparation)
(preparation of)


RN 111384-11-3 CAPLUS

CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-1-piperidinyl- (CA INDEX NAME)




RN 115101-88-7 CAPLUS

CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 115163-48-9 CAPLUS

CN Methanone, [1-(2-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 07:48:08 ON 09 OCT 2008